Page last updated: 2024-12-06

atovaquone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Atovaquone is a synthetic hydroxynaphthoquinone that acts as an antimalarial drug. It inhibits mitochondrial cytochrome bc1 complex, a key enzyme in the electron transport chain of the malaria parasite Plasmodium falciparum. Atovaquone is typically administered in combination with proguanil, a dihydrofolate reductase inhibitor, to improve efficacy and reduce the risk of resistance. This combination is known as Malarone and is used for both prophylaxis and treatment of malaria. Atovaquone is also used in combination with other drugs for the treatment of Pneumocystis jirovecii pneumonia, a serious opportunistic infection in people with weakened immune systems. Atovaquone is a potent inhibitor of the cytochrome bc1 complex, which is essential for cellular respiration in many organisms, including parasites. This mechanism of action makes atovaquone effective against a wide range of parasites, including those that cause malaria, toxoplasmosis, and babesiosis. Studies are ongoing to investigate the potential use of atovaquone in combination with other drugs for the treatment of various parasitic infections and cancers. The synthesis of atovaquone involves a multi-step process starting from commercially available starting materials. The drug is produced on a large scale by a number of pharmaceutical companies. Atovaquone is generally well-tolerated, but it can cause side effects, including headache, nausea, and vomiting. The drug is contraindicated in patients with hypersensitivity to atovaquone or any of its ingredients. '
```

Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID74989
CHEMBL ID222334
CHEMBL ID471792
CHEMBL ID519462
CHEBI ID575568
CHEBI ID95346
SCHEMBL ID637069
SCHEMBL ID21695
SCHEMBL ID21694
SCHEMBL ID1649508
SCHEMBL ID1542719
SCHEMBL ID9975229
SCHEMBL ID9975142
MeSH IDM0173858

Synonyms (201)

Synonym
BIDD:GT0849
smr001233220
MLS002153863
AKOS005567953
AB00053222-03
bw-a 566c
1,4-naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-
2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
crl-8131 & atovaquone
ato & il-12
atovaquone & interleukin 12
DIVK1C_006782
2-(trans-4-(p-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
atavaquone
1,4-naphthalenedione, 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-, trans-
hsdb 7083
mepron (antipneumocystic)
drg-0084
bw 566c
1,4-naphthalenedione, 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-
566c
bw 566c-80
2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione
SPECTRUM_001743
BPBIO1_000603
cas-95233-18-4
NCGC00016961-01
PRESTWICK3_000534
566c80
bw 566c80
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-naphthalene-1,4-dione
2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
BSPBIO_000547
BSPBIO_002681
PRESTWICK2_000534
AB00513855
atovaquone
wellvone
C06835
acuvel
95233-18-4
mepron
DB01117
mepron (tn)
atovaquone (jan/usp/inn)
D00236
NCGC00095113-01
NCGC00095113-02
KBIOGR_001594
KBIO1_001726
KBIO3_001901
KBIO2_004791
KBIO2_002223
KBIO2_007359
KBIOSS_002223
SPECTRUM4_001117
SPECTRUM3_000991
SPBIO_002468
PRESTWICK0_000534
SPECPLUS_000686
SPBIO_001849
PRESTWICK1_000534
SPECTRUM2_001665
SPECTRUM1504210
SPECTRUM5_001382
NCGC00016961-02
HMS2089M14
HMS2093C10
nsc-759582
3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione
2-((1r,4r)-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione
CHEBI:575568 ,
HMS1569L09
HMS1922F19
94015-53-9
STK636160
HMS2096L09
atovaquone [usan:usp:inn:ban]
y883p1z2lt ,
unii-y883p1z2lt
nsc 759582
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1.4-naphthoquinone
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-napthoquinone
2-[4-(4-chlorophenyl)cyclohexy]-3-hydroxy-1,4-naphthoquinone
CHEMBL222334
pharmakon1600-01504210
nsc759582
tox21_110714
dtxsid7022629 ,
dtxcid602629
trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione
HMS2235N08
CHEMBL471792
AKOS015961933
CCG-39090
NCGC00016961-04
NCGC00016961-03
CHEMBL519462
bw-566c-80
2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione
FT-0602868
NCGC00016961-07
AKOS015895691
2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthalenedione
S3079
HMS3369N09
KUCQYCKVKVOKAY-OTVXOJSOSA-N
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-dihydronaphthalene-1,4-dione
atovaquone [vandf]
malarone component atovaquone
atovaquone [hsdb]
atovaquone [usp monograph]
atovaquone [orange book]
atovaquone [jan]
atovaquone [usp-rs]
atovaquone [usan]
atovaquone [who-dd]
atovaquone component of malarone
atovaquone [mi]
atovaquone component of malarone pediatric
atovaquone [ep monograph]
malarone pediatric component atovaquone
FD7252
atovaquone [inn]
atovaquone [mart.]
CCG-220534
HY-13832
SCHEMBL637069
SCHEMBL21695
SCHEMBL21694
NCGC00016961-06
tox21_110714_1
SCHEMBL1649508
3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxy-naphthalene-1,2-dione
SCHEMBL1542719
KUCQYCKVKVOKAY-CTYIDZIISA-N
trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
cis-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
SCHEMBL9975229
SCHEMBL9975142
2-[trans-4-(p-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthoquinone, trans-
bw-556c-80
gtpl9695
3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthalenedione
AC-30251
AB00053222_04
AB00053222_05
137732-39-9
atovaquone, >=98% (hplc)
mfcd00889188
SR-05000001438-5
sr-05000001438
CHEBI:95346
3-[4-(p-chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthoquinone
HMS3651N20
SR-05000001438-4
SR-05000001438-2
SR-05000001438-1
atovaquone; 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione; 566c80
SBI-0052893.P002
HMS3713L09
2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione
SW219222-1
cis-atovaquone
DTXSID20916694
1,4-naphthalenedione, 2-[cis-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-
Q418179
cis -2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione
trans-2-(4-(4-chlorophenyl) cyclohexyl)-3-hydroxynaphthalene-1,4-dione
2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione
F18448
cis-atovaquone (racemic)
atovaquone (atavaquone)
2-(cis-4-(4-chlorophenyl)cyclohexyl)-3-hydroxynaphthalene-1,4-dione
AS-12809
BCP09477
AMY15339
bdbm192009
A13708
EN300-120639
cis-2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
2-(cis-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthalenedione
1,4-naphthalenedione, 2-(cis-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-
f1w7quv0ki ,
unii-f1w7quv0ki
NCGC00016961-11
A853147
atovaquone 100 microg/ml in acetonitrile
STARBLD0018905
atovaquona
atovacuona
atovaquone- bio-x
BA164228
atovaquone for system suitability
EN300-731648
2-hydroxy-3-[(1r,4r)-4-(4-chlorophenyl)cyclohexyl]-1,4-dihydronaphthalene-1,4-dione
1,2-naphthalenedione, 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxy-
Z2588038997
cis-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone; atovaquone related compound a (usp); atovaquone imp. b (ep); 296c85; usp atovaquone related compound a; gr 261266x

Research Excerpts

Overview

Atovaquone is an FDA-approved antiparasitic and antifungal therapeutic. It is currently used as a prophylactic agent to prevent Pneumocystis carinii pneumonia (PCP) infections in acute myeloid leukemia (AML) patients after receiving hematopoietic stem cell transplantation (HSCT)

ExcerptReferenceRelevance
"Atovaquone is an antimalarial drug, and its anticancer effect has recently been demonstrated in several cancer models in vitro and in vivo, but it has not been examined in the treatment of colorectal cancer."( Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway.
Guo, P; Li, J; Liu, B; Liu, W; Yao, P; Zhao, G; Zheng, X, 2023
)
3.07
"Atovaquone is an FDA-approved antiparasitic and antifungal therapeutic that is currently used as a prophylactic agent to prevent Pneumocystis carinii pneumonia (PCP) infections in acute myeloid leukemia (AML) patients after receiving hematopoietic stem cell transplantation (HSCT). "( Liquid Chromatography-Tandem Mass Spectrometry-Based Therapeutic Monitoring of Plasma Atovaquone Concentrations in Pediatric Patients.
Devaraj, S; Horvath, TD, 2024
)
3.11
"Atovaquone (ATQ) is a poorly soluble drug. "( Quantification of atovaquone from amorphous solid dispersion formulation using HPLC: An in vitro and ex vivo investigation.
Aminu, N; Chan, SY; Goh, CF; Teoh, XY, 2021
)
2.4
"Atovaquone (ATQ) is a drug used to prevent and treat malaria that functions by targeting the "( Decoding the Molecular Effects of Atovaquone Linked Resistant Mutations on
Chebon-Bore, L; Khairallah, A; Manyumwa, CV; Sanyanga, TA; Tastan Bishop, Ö, 2021
)
2.34
"Atovaquone is a powerful suppressor of protozoan parasites with a broad-spectrum activity, but an extremely low water solubility and bioavailability."( Nanoemulsion of atovaquone as a promising approach for treatment of acute and chronic toxoplasmosis.
Amani, A; Azami, SJ; Faramarzi, MA; Keshavarz, H; Mahmoudi, M; Mohebali, M; Najafi-Taher, R; Shojaee, S, 2018
)
1.55
"Atovaquone is a FDA-approved antibiotic but is also known as a mitochondrial inhibitor."( Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy.
Cao, J; Chen, D; Sun, X; Zhang, X, 2018
)
1.46
"Atovaquone is a ubiquinone antagonist that inhibits mitochondrial electron transport and collapses mitochondrial membrane potential."( Atovaquone and proguanil hydrochloride: a review of nonclinical studies.
Dickins, M; Gutteridge, W; Pudney, M; Woolley, JL; Zeman, A, 1999
)
2.47
"Atovaquone is a highly lipophilic compound with low aqueous solubility, the absorption of which is limited by the rate and extent of dissolution. "( Clinical pharmacology of atovaquone and proguanil hydrochloride.
Beerahee, M, 1999
)
2.05
"Atovaquone is a component of Malarone, a widely prescribed antimalarial combination, that targets malaria respiration. "( Atovaquone tolerance in Plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor.
Guler, JL; Phillips, MA; Rathod, PK; White, J, 2015
)
3.3
"Atovaquone is an effective antiprotozoal agent against toxoplasmosis with minor side effects."( [Effects of atovaquone and astragalus combination on the treatment and IL-2, IL-12, IFN-γ levels on mouse models of acute toxoplasmosis].
Büyükbaba Boral, O; Kaşali, K; Sönmez, N; Tekeli, F, 2014
)
1.5
"Atovaquone is a hydroxynaphthoquinone with selective action in the mitochondrial respiratory chain of malaria parasite. "( Microbial Metabolism of Atovaquone and Cytotoxicity of the Produced Phase I Metabolite.
Alves Dos Santos, R; de Oliveira Silva, E; Dos Santos Gonçalves, N; Jacometti Cardoso Furtado, NA, 2016
)
2.18
"Atovaquone-Proguanil is a WHO approved fixed dose combination used to tackle the problem of emerging resistance."( Bioavailability enhancement of atovaquone using hot melt extrusion technology.
Borhade, V; Deshpande, V; Gokarna, V; Kate, L; Pathak, S; Patravale, V; Prabhu, P; Sharma, S, 2016
)
1.44
"Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000. "( Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.
Cappello, AR; Fiorillo, M; Krstic-Demonacos, M; Lamb, R; Lisanti, MP; Martinez-Outschoorn, UE; Mutti, L; Sotgia, F; Tanowitz, HB, 2016
)
2.26
"Atovaquone is a ubiquinone analogue, and decreases the OCR by inhibiting mitochondrial complex III."( The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia.
Anbalagan, S; Ashton, TM; Buffa, FM; Fokas, E; Folkes, LK; Hammond, EM; Higgins, GS; Huether, M; Kelly, CJ; Kunz-Schughart, LA; McKenna, WG; Muschel, RJ; Pirovano, G; Stratford, M, 2016
)
1.49
"Atovaquone is a substituted 2-hydroxy-naphthoquinone used therapeutically against Plasmodium falciparum (malaria) and Pneumocystis pathogens. "( Probing binding determinants in center P of the cytochrome bc(1) complex using novel hydroxy-naphthoquinones.
Covian, R; Gribble, GW; Hughes, LM; Trumpower, BL, 2010
)
1.8
"Atovaquone is an anti-malarial drug used in combination with proguanil (e.g. "( Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression.
Abd Majid, R; Al-Helal, M; Antoine, T; Biagini, GA; Fisher, N; Johnson, DJ; Lawrenson, AS; O'Neill, PM; Ranson, H; Ward, SA; Warman, AJ, 2012
)
2.09
"Atovaquone is a drug of choice but not approved for use in congenital Toxoplasmosis."( Atovaquone ameliorate gastrointestinal toxoplasmosis complications in a pregnancy model.
Oz, HS; Tobin, T, 2012
)
2.54
"Atovaquone/proguanil is a fixed-dose combination tablet of two antimalarial agents and is highly effective for the prevention of Plasmodium falciparum malaria. "( Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
McKeage, K; Scott, L, 2003
)
3.2
"Atovaquone/proguanil is a fixed-dose combination antimalarial tablet that provides effective prophylaxis of P. "( Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
McKeage, K; Scott, L, 2003
)
3.2
"Atovaquone is a substituted 2-hydroxynaphthoquinone that is used therapeutically to treat Plasmodium falciparum malaria, Pneumocystis carinii pneumonia, and Toxoplasma gondii toxoplasmosis. "( Molecular basis for atovaquone binding to the cytochrome bc1 complex.
Hill, P; Hunte, C; Kessl, JJ; Lange, BB; Merbitz-Zahradnik, T; Meshnick, S; Meunier, B; Pálsdóttir, H; Trumpower, BL; Zwicker, K, 2003
)
2.09
"Atovaquone-proguanil is a safe and effective alternative to current recommended regimens for prophylaxis and treatment of malaria."( Atovaquone-proguanil for prophylaxis and treatment of malaria.
Ensom, MH; Marra, F; Salzman, JR, 2003
)
3.2
"Atovaquone is a new broad-spectrum antiprotozoal drug with high in vitro activity against multidrug-resistant Plasmodium falciparum. "( Molecular epidemiology of malaria in Cameroon. XVII. Baseline monitoring of atovaquone-resistant Plasmodium falciparum by in vitro drug assays and cytochrome b gene sequence analysis.
Basco, LK, 2003
)
1.99
"Atovaquone is a substituted hydroxynaphthoquinone that is widely used to prevent and clear Plasmodium falciparum malaria and Pneumocystis jirovecii pneumonia. "( Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae.
Hill, P; Kessl, JJ; Lange, BB; Meshnick, SR; Meunier, B; Trumpower, BL, 2004
)
2.09
"Atovaquone is a new anti-malarial agent that specifically targets the cytochrome bc1 complex and inhibits parasite respiration. "( Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae.
Ha, KH; Hill, P; Kessl, JJ; Lange, BB; Merritt, AK; Meshnick, SR; Meunier, B; Trumpower, BL, 2005
)
1.77
"Atovaquone is an antiparasitic drug that selectively inhibits electron transport through the parasite mitochondrial cytochrome bc1 complex and collapses the mitochondrial membrane potential at concentrations far lower than those at which the mammalian system is affected. "( Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system.
Cooley, JW; Daldal, F; Darrouzet, E; Mather, MW; McIntosh, MT; Vaidya, AB; Valkova-Valchanova, M, 2005
)
2.01
"Atovaquone-proguanil is an effective and increasingly popular antimalarial choice when used alone or with artesunate in areas of drug resistance."( Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate.
Gupta, RK; Looareesuwan, S; Nosten, F; Paiphun, L; Slight, T; Van Vugt, M; White, NJ, 2005
)
1.31
"Atovaquone is a substituted hydroxynaphthoquinone that is used therapeutically for treating Plasmodium falciparum malaria, Pneumocystis jirovecii pneumonia and Toxoplasma gondii toxoplasmosis. "( Modeling the molecular basis of atovaquone resistance in parasites and pathogenic fungi.
Kessl, JJ; Meshnick, SR; Trumpower, BL, 2007
)
2.07
"Atovaquone-proguanil is a recent antimalarial drug licensed in France for the uncomplicated P."( [Tolerance and efficacy of atovaquone-proguanil for the treatment of paediatric imported Plasmodium falciparum malaria in France: clinical practice in a university hospital in Paris].
Angoulvant, F; Bigirimana, Z; Blondé, R; Bourdon, O; Bourrillon, A; D'Ortenzio, E; Faye, A; Fenneteau, O; Holvoet, L; Le Bras, J; Lorrot, M; Matheron, S; Naudin, J; Vitoux, C, 2008
)
1.36
"Atovaquone-proguanil is an efficient and well-tolerated antimalarial treatment for uncomplicated P. "( [Tolerance and efficacy of atovaquone-proguanil for the treatment of paediatric imported Plasmodium falciparum malaria in France: clinical practice in a university hospital in Paris].
Angoulvant, F; Bigirimana, Z; Blondé, R; Bourdon, O; Bourrillon, A; D'Ortenzio, E; Faye, A; Fenneteau, O; Holvoet, L; Le Bras, J; Lorrot, M; Matheron, S; Naudin, J; Vitoux, C, 2008
)
2.09
"Atovaquone is an effective and well tolerated substance for the treatment of ocular toxoplasmosis. "( [Treatment of toxoplasmosis retinochoroiditis with atovaquone in an AIDS patient].
Althaus, C; Armbrecht, C; Jablonowski, H; Schimkat, M; Sundmacher, R, 1995
)
1.99
"Atovaquone is a new hydroxynapthoquinone antiprotozoal agent active against Pneumocystis carinii in vitro and in animal models. "( Clinical experience with atovaquone: a new drug for treating Pneumocystis carinii pneumonia.
Daar, ES; Epstein, LJ; Meyer, RD; Mohsenifar, Z; Yeh, V, 1994
)
2.03
"1. Atovaquone is a potent antiprotozoal slowly and irregularly absorbed after administration as tablets to fasting volunteers. "( Examination of some factors responsible for a food-induced increase in absorption of atovaquone.
Holdich, T; Meire, H; Mercer, AJ; Peck, RW; Posner, J; Ridout, G; Rolan, PE; Weatherley, BC, 1994
)
1.13
"Atovaquone is a novel hydroxynaphthoquinone with potent activity against Pneumocystis carinii and Toxoplasma gondii. "( Atovaquone: a review.
Flaherty, JF; Haile, LG, 1993
)
3.17
"Atovaquone (566C80) is a new hydroxynaphthoquinone with activity against P."( Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Bozzette, SA; Chan, C; Clumeck, N; Frame, P; Hughes, W; Kramer, F; Lancaster, D; Leoung, G; Masur, H; Safrin, S, 1993
)
1.37
"Atovaquone is a novel hydroxynaphthoquinone with broad spectrum anti-protozoal activity."( Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.
Canfield, CJ; Hutchinson, DB; Kyle, DE; Looareesuwan, S; Viravan, C; Webster, HK, 1996
)
1.34
"Atovaquone is a potent antiprotozoal compound for use in immunocompromised patients who are intolerant of conventional therapies."( Determination of the potent antiprotozoal compound atovaquone in plasma using liquid-liquid extraction followed by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Hannan, SL; Jones, AE; Ridout, GA, 1996
)
1.27
"Atovaquone is an effective and well tolerated drug for the treatment of active ocular toxoplasmosis in immunocompetent patients. "( [Treatment of toxoplasmosis retinochoroiditis with atovaquone in an immunocompetent patient].
Althaus, C; Hudde, T; Schimkat, M; Sundmacher, R, 1996
)
1.99
"Atovaquone is an antiprotozoal compound with good in vitro stability against metabolic inactivation. "( Disposition of atovaquone in humans.
Benjamin, I; Mercer, AJ; Posner, J; Rolan, PE; Tate, E, 1997
)
2.09
"Atovaquone is a promising alternative for the treatment of ocular toxoplasmosis in immunocompetent patients."( Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients.
Jaffe, GJ; Pearson, PA; Piracha, AR; Sen, HA, 1999
)
2.47
"Atovaquone is a broad-spectrum antiprotozoal drug with a novel mechanism of action, via inhibition of parasite mitochondrial electron transport, and a favorable safety profile."( Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.
Canfield, CJ; Chulay, JD; Hutchinson, DB; Looareesuwan, S, 1999
)
1.43
"Atovaquone is an antimalarial agent that specifically inhibits the cytochrome bc(1) complex of the cytochrome pathway. "( Plasmodium falciparum: the effects of atovaquone resistance on respiration.
Kyle, D; Lang-Unnasch, N; Suswam, E, 2001
)
2.02
"Atovaquone is a relatively weak inhibitor of CYP2C9-mediated SMX-HA formation in vitro. "( Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation.
Miller, JL; Trepanier, LA, 2002
)
2.12
"Atovaquone is a structural analog of ubiquinone, which binds to the mitochondrial cytochrome bc(1) complex and inhibits electron transport."( Are cytochrome b gene mutations the only cause of atovaquone resistance in Pneumocystis?
Kaneshiro, ES, 2001
)
1.29
"Atovaquone is a well-tolerated drug that appears to be an effective alternative for patients with toxoplasmosis who are intolerant of standard therapies."( Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program.
Kovacs, JA, 1992
)
1.38

Effects

Atovaquone has a novel mechanism of action that has been hypothesized to result in microbicidal rather than microbistatic activity against Pneumocystis carinii.

Atovaquone has been investigated as an alternative agent for oral use in the treatment of both mild to moderate Pneumocystis carinii pneumonia (PCP) and toxoplasmosis. In the United States there is no upper limit for the duration of use.

ExcerptReferenceRelevance
"Atovaquone (ATV) has a growth inhibitory effect against Babesia gibsoni. "( The effect of atovaquone on the mitochondrial membrane potential of Babesiagibsoni.
Iguchi, A; Kobayashi, S; Mizukami, M; Sato, R; Takeuchi, T; Uchida, N; Yamasaki, M, 2022
)
2.52
"Atovaquone-proguanil has an excellent safety profile during both prophylaxis and treatment courses, with severe adverse events rarely reported."( Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).
Boggild, AK; Kain, KC; Lewis, LS; Parise, ME, 2007
)
2.5
"Atovaquone has a novel mechanism of action that has been hypothesized to result in microbicidal rather than microbistatic activity against Pneumocystis carinii."( Atovaquone: a new antipneumocystis agent.
Artymowicz, RJ; James, VE, 1993
)
2.45
"Atovaquone (ATV) has a growth inhibitory effect against Babesia gibsoni. "( The effect of atovaquone on the mitochondrial membrane potential of Babesiagibsoni.
Iguchi, A; Kobayashi, S; Mizukami, M; Sato, R; Takeuchi, T; Uchida, N; Yamasaki, M, 2022
)
2.52
"Atovaquone has antifungal activity against Aspergillus and Fusarium clinical isolates, with Fusarium species being more sensitive to atovaquone than Aspergillus species. "( Atovaquone Impairs Growth of Aspergillus and Fusarium Keratitis Isolates by Modulating Mitochondrial Function and Zinc Homeostasis.
Clark, HL; de Jesus, T; Ghannoum, MG; Minns, MS; Pearlman, E; Sun, Y, 2018
)
3.37
"Atovaquone/proguanil has been used to provide radical cure of asymptomatic Plasmodium falciparum infections prior to initiation of placebo-controlled trials of malaria prophylaxis."( Atovaquone and proguanil hydrochloride for treatment of malaria.
Chulay, JD; Kremsner, PG; Looareesuwan, S, 1999
)
2.47
"Atovaquone-proguanil has been evaluated for treatment of acute, uncomplicated malaria caused by Plasmodium falciparum in 8 clinical trials. "( Atovaquone-proguanil for prophylaxis and treatment of malaria.
Ensom, MH; Marra, F; Salzman, JR, 2003
)
3.2
"Atovaquone-proguanil has recently been introduced for the treatment and prophylaxis of malaria. "( Short communication: Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana.
Bienzle, U; Ehrhardt, S; Jelinek, T; Mockenhaupt, FP; Muehlen, M; Otchwemah, R; Schreiber, J, 2004
)
2
"Atovaquone-proguanil has been shown to be effective and well tolerated for malaria prophylaxis in residents of countries of endemicity and in nonimmune adult travelers, but data about traveling children are limited. "( Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study.
Camus, D; De Boever, EH; Djossou, F; Dutoit, E; Hedgley, C; Høgh, B; Malvy, D; Miller, GB; Roskell, NS; Schilthuis, HJ, 2004
)
3.21
"Atovaquone/proguanil has been registered in Europe for travels of up to four weeks, but in the United States there is no upper limit for the duration of use."( [Malaria chemoprophylaxis].
Petersen, JE, 2005
)
1.05
"Atovaquone-proguanil has an excellent safety profile during both prophylaxis and treatment courses, with severe adverse events rarely reported."( Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).
Boggild, AK; Kain, KC; Lewis, LS; Parise, ME, 2007
)
2.5
"Atovaquone has been investigated as an alternative agent for oral use in the treatment of both mild to moderate Pneumocystis carinii pneumonia (PCP) and toxoplasmosis, opportunistic infections commonly experienced by patients with AIDS. "( Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.
Goa, KL; Spencer, CM, 1995
)
3.18
"Atovaquone has a novel mechanism of action that has been hypothesized to result in microbicidal rather than microbistatic activity against Pneumocystis carinii."( Atovaquone: a new antipneumocystis agent.
Artymowicz, RJ; James, VE, 1993
)
2.45
"Atovaquone has not been studied for PCP prophylaxis."( Atovaquone: a review.
Flaherty, JF; Haile, LG, 1993
)
2.45
"Atovaquone has the potential to reduce the risk of recurrent disease."( Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease.
Gormley, PD; Lightman, S; Minnasian, D; Pavesio, CE, 1998
)
1.02
"Atovaquone has been shown to inhibit the cytochrome bc(1) (CYT bc(1)) complex of the electron transport chain of malaria parasites."( Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site.
Chen, N; Cheng, Q; Korsinczky, M; Kotecka, B; Rieckmann, K; Saul, A, 2000
)
1.26

Actions

Atovaquone was shown to inhibit the respiratory chain of T. It could inhibit EMT by inhibiting NF-κB (p-P65) and related inflammatory factors.

ExcerptReferenceRelevance
"Atovaquone could inhibit EMT by inhibiting NF-κB (p-P65) and related inflammatory factors."( Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway.
Guo, P; Li, J; Liu, B; Liu, W; Yao, P; Zhao, G; Zheng, X, 2023
)
3.07
"Atovaquone appears to increase the AUC of zidovudine by inhibiting the glucuronidation of zidovudine."( Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine.
Chambers, HF; Goldstein, D; Lee, BL; Sadler, B; Täuber, MG, 1996
)
2.46
"Atovaquone was shown to inhibit the respiratory chain of T."( Respiration and oxidative phosphorylation in the apicomplexan parasite Toxoplasma gondii.
Moreno, SN; Rodrigues, CO; Uyemura, SA; Vercesi, AE; Zhong, L, 1998
)
1.02

Treatment

Atovaquone treatment partially but significantly protected the dams from the severity of hepatitis, splenomegaly, colitis, myocarditis, and pain related responses. Two patients did not receive a transplant and two patients (10%) were removed due to a protocol violation.

ExcerptReferenceRelevance
"Atovaquone treatment partially but significantly protected the dams from the severity of hepatitis, splenomegaly, colitis, myocarditis, and pain related responses as well as fetal demise."( Atovaquone ameliorate gastrointestinal toxoplasmosis complications in a pregnancy model.
Oz, HS; Tobin, T, 2012
)
2.54
"One atovaquone/proguanil treatment failure was documented; the post-treatment isolate had an atovaquone susceptibility of 8230 nM and the Ser268 Cytb change; the pre-treatment isolate, obtained 4 weeks previously, was Cytb Tyr268 (wild-type)."( Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers.
Bigot, P; Durand, R; Le Bras, J; Musset, L; Parzy, D; Pradines, B, 2006
)
1.14
"Four atovaquone-treated patients were removed from study; two patients (10%) did not receive a transplant and two patients (10%) were removed due to a protocol violation."( A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby, C; Finkelstein, D; Fishman, J; McAfee, S; Sackstein, R; Spitzer, T, 1999
)
0.99
"Treatment with atovaquone-proguanil led to resolution of fever and restoration of platelet count in two days."( Plasmodium knowlesi malaria in a traveller returning from the Philippines to Italy, 2016.
Akkouche, W; Barzon, L; Biasolo, MA; De Canale, E; Marini, G; Masiero, S; Menegotto, N; Palù, G; Sgarabotto, D, 2017
)
0.79

Toxicity

Atovaquone/proguanil was safe and well tolerated in this group of long-term nonimmune travelers. None of the 16 patients treated with atovaqu one experienced treatment-associated adverse effects. Three (15%) of the 20 atovaqone-proguAnil-treated adults had adverse events.

ExcerptReferenceRelevance
" The only drug-related adverse effect was a maculopapular rash in one patient that resolved without discontinuation of the drug."( Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men.
Flynn, PM; Fullen, G; Hetherington, SV; Hughes, WT; Kennedy, W; Lancaster, DJ; Palte, S; Rosenbaum, D; Shenep, JL; Stein, DS, 1991
)
0.28
"Atovaquone was compared to trimethoprim-sulfamethoxazole (TMP-SMZ) for the relationship of time receiving therapy, plasma drug concentrations, and incidence of adverse reactions in patients with AIDS-associated Pneumocystis carinii pneumonia."( Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia.
Hughes, WT; LaFon, SW; Masur, H; Scott, JD, 1995
)
1.97
" The results showed m-atovaquone to be safe and well tolerated."( Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group.
Beauchamp, B; Dorenbaum, A; Hughes, W; McNamara, J; Moye, J; Purdue, L; Rogers, M; Sadler, B; van Dyke, R; Xu, J; Yogev, R, 1998
)
0.86
"Currently recommended prophylactic regimens for Plasmodium falciparum malaria are associated with a high incidence of adverse events and/or suboptimal efficacy."( Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria.
Aleman, GM; Gordon, DM; Klotz, FW; Oloo, AJ; Sadie, D; Scott, TR; Shanks, GD, 1998
)
0.61
" Malaria blood smears were prepared on a weekly basis and a failure of chemoprophylaxis was defined as any subject who had a positive blood smear, or who withdrew from the study due to a treatment-related adverse event."( A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia.
Chisdaka, N; Mulenga, M; Roskell, NS; Scott, TR; Sukwa, TY, 1999
)
0.52
" Adverse events were generally typical of malaria symptoms and each occurred in < 10% of the patients in either group, with the exception of increased vomiting found in the atovaquone/proguanil group."( Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand.
Canfield, CJ; Chalermarut, K; Hutchinson, DB; Looareesuwan, S; Rattanapong, Y; Wilairatana, P, 1999
)
0.81
" Prophylactic success was summarized using a 95% confidence interval for the proportion of subjects who did not develop parasitemia or who withdrew due to a treatment-related adverse event."( Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa.
Duvenage, CS; Roskell, NS; Scott, TR; van der Berg, JD, 1999
)
0.61
" None of the 16 patients treated with atovaquone experienced treatment-associated adverse effects."( A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby, C; Finkelstein, D; Fishman, J; McAfee, S; Sackstein, R; Spitzer, T, 1999
)
0.81
"We performed a prospective, double-blind, randomized study to compare the occurrence of neuropsychiatric adverse events and concentration impairment during prophylactic use of either mefloquine or atovaquone plus chloroguanide (INN, proguanil)."( Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events.
Ditters, JM; Ligthelm, RJ; Overbosch, D; Stricker, BH; Sturkenboom, MC; van Riemsdijk, MM, 2002
)
1.95
"No serious adverse events occurred."( The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults.
Petersen, E, 2003
)
0.68
"Atovaquone/proguanil was safe and well tolerated in this group of long-term nonimmune travelers."( The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults.
Petersen, E, 2003
)
2.12
"We prospectively studied adverse reactions reported by long-term travelers using atovaquone/proguanil among a population intolerant to mefloquine."( Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries.
Overbosch, D, 2003
)
0.78
" Comparison with data from previous, larger atovaquone/proguanil studies shows that the adverse events reported by the long-term atovaquone/proguanil users are no different in type and frequency of occurrence to those travel-related health problems normally encountered in the Tropics."( Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries.
Overbosch, D, 2003
)
0.82
" The outcome measures were parasite clearance time, fever clearance time, efficacy, and adverse events profile."( A randomized open label clinical trial to compare the efficacy and safety of intravenous quinine followed by oral malarone vs. intravenous quinine followed by oral quinine in the treatment of severe malaria.
Ayuo, PO; Esamai, F; Jakait, B; Obala, A; Ong'or, WO; Tenge, CN, 2005
)
0.33
" An effective and safe prophylactic antimalarial drug is needed."( Malaria prophylaxis for aircrew: safety of atovaquone/proguanil in healthy volunteers under aircraft cabin pressure conditions.
Krul, AJ; Simons, R; Valk, PJ,
)
0.39
" No significant differences were found between the effects of placebo and A/P on vigilance, alertness, complex information processing, sleep duration and quality, and the occurrence of adverse effects."( Malaria prophylaxis for aircrew: safety of atovaquone/proguanil in healthy volunteers under aircraft cabin pressure conditions.
Krul, AJ; Simons, R; Valk, PJ,
)
0.39
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Three (15%) of the 20 atovaquone-proguanil-treated adults had adverse events (AEs), all of which were transient elevations of liver enzymes, while 19 (38%) of the 50 mefloquine-treated adults had AEs, including dizziness in 8 (16%) and nausea/vomiting in 7 (14%)."( Efficacy and safety of atovaquone-proguanil compared with mefloquine in the treatment of nonimmune patients with uncomplicated P. falciparum malaria in Japan.
Hitani, A; Kimura, M; Nakamura, T; Nawa, Y; Ohtomo, H, 2006
)
0.96
" These observations suggest that A/P is also a safe and efficacious drug for the long-term chemoprophylaxis of falciparum malaria."( The safety and tolerance of atovaquone/proguanil for the long-term prophylaxis of plasmodium falciparum malaria in non-immune travelers and expatriates [corrected].
Koene, HR; Overbosch, D; Spong, K; van Genderen, PJ,
)
0.43
" It was also considered safe and better tolerated with fewer treatment-related adverse events that could lead to premature discontinuation of prophylaxis than in controls."( A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria.
Hunter, PR; Nakato, H; Vivancos, R, 2007
)
0.57
" The results support the continued safe and efficacious use of artemether-lumefantrine in uncomplicated falciparum malaria."( Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.
Barón, C; Carrasquilla, G; Cousin, M; Fisher, LM; Lefèvre, G; Monsell, EM; Sander, O; Walter, V, 2012
)
0.38
" falciparum malaria who developed a moderate liver function disturbance, no significant adverse effects were observed."( Efficacy and safety of atovaquone-proguanil in treating imported malaria in Japan: the second report from the research group.
Kikuchi, T; Kimura, M; Koga, M; Maruyama, H; Miura, T, 2012
)
0.69
"We retrospectively examined the application and adverse events associated with atovaquone use between January 1997 and March 2012."( [Status of use and side effects of atovaquone for the treatment and prevention of pneumocystis pneumonia in HIV infected patients in Japan--from 1997 to 2012--The Clinical Study Group for AIDS Drugs, supported by Health and Labor Science Grants from the M
Fukutake, K; Sekine, Y; Shinozawa, K; Yamamoto, Y; Yotsumoto, M, 2013
)
0.89
" Fifty-seven adverse events in 39 patients were reported."( [Status of use and side effects of atovaquone for the treatment and prevention of pneumocystis pneumonia in HIV infected patients in Japan--from 1997 to 2012--The Clinical Study Group for AIDS Drugs, supported by Health and Labor Science Grants from the M
Fukutake, K; Sekine, Y; Shinozawa, K; Yamamoto, Y; Yotsumoto, M, 2013
)
0.67
"The produced metabolite was more toxic than atovaquone and was not selective to normal or cancer cell lines."( Microbial Metabolism of Atovaquone and Cytotoxicity of the Produced Phase I Metabolite.
Alves Dos Santos, R; de Oliveira Silva, E; Dos Santos Gonçalves, N; Jacometti Cardoso Furtado, NA, 2016
)
1
" All three treatments showed good tolerance and safety with scarce adverse events observed."( Efficacy, safety and tolerance of imidocarb dipropionate versus atovaquone or buparvaquone plus azithromycin used to treat sick dogs naturally infected with the Babesia microti-like piroplasm.
Bartolomé, A; Checa, R; Gálvez, R; González-Fraga, JL; Marino, V; Miró, G; Montoya, A; Ortega, N, 2017
)
0.69
" Passively reported adverse event data may provide additional information on the safety of AP during pregnancy."( Safety of atovaquone-proguanil during pregnancy.
Gutman, JR; Mayer, RC; Tan, KR, 2019
)
0.92
"We analysed adverse event data on pregnancy and birth outcomes following accidental exposures to AP during pregnancy, which were passively reported to GlaxoSmithKline LLC (GSK) between 13 May 1997 and 15 August 2017."( Safety of atovaquone-proguanil during pregnancy.
Gutman, JR; Mayer, RC; Tan, KR, 2019
)
0.92
" A systematic review was conducted to evaluate the incidence of adverse outcomes after atovaquone-proguanil (AP) exposure during pregnancy."( The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: A systematic review.
Andrejko, KL; Bartlett, E; Gutman, JR; Kovacs, S; Mayer, RC; Slutsker, E; Tan, KR,
)
0.71
" Overall proportions and 95% confidence intervals of adverse outcomes were determined by pooling data across studies."( The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: A systematic review.
Andrejko, KL; Bartlett, E; Gutman, JR; Kovacs, S; Mayer, RC; Slutsker, E; Tan, KR,
)
0.49
" The overall proportions and 95% confidence intervals (CI) of adverse outcomes reported for the 446 women exposed to AP include miscarriage (8."( The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: A systematic review.
Andrejko, KL; Bartlett, E; Gutman, JR; Kovacs, S; Mayer, RC; Slutsker, E; Tan, KR,
)
0.49
" Adverse events occurred in 8 of 8 (100%) of participants receiving ATV-PG/AQ, 11 of 12 (91."( Unanticipated CNS Safety Signal in a Placebo-Controlled, Randomized Trial of Co-Administered Atovaquone-Proguanil and Amodiaquine.
Abla, N; Chalon, S; Chughlay, MF; Haouala, A; Hutter, B; Lorch, U; Macintyre, F; Marie Tchouatieu, A, 2022
)
0.94

Pharmacokinetics

A phase I dose-escalating safety and pharmacokinetic study evaluated an oral suspension of micronized atovaquone (m-atovaqu one) in infants and children stratified into age groups from 1 month to 12 years of age.

ExcerptReferenceRelevance
" Pharmacokinetic parameters were determined by noncompartmental methods, and statistical comparison of parameters for single doses was performed by analysis of variance."( Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients.
Dixon, R; Posner, J; Pozniak, AL; Rolan, P; Watt, HM, 1996
)
0.52
"The potential pharmacokinetic interaction between atovaquone and phenytoin was investigated in 12 healthy male volunteers."( Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers.
Davis, JD; Dixon, R; Khan, AZ; Posner, J; Rolan, PE; Toon, S, 1996
)
1.99
"05) in the area under the plasma drug concentration-time curve (AUC), apparent oral clearance (CL/F) and elimination half-life (t1/2) of PROG between patients given PROG alone and PROG/ ATQ."( Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone.
Edstein, MD; Kyle, DE; Looareesuwan, S; Viravan, C, 1996
)
0.52
"A phase I dose-escalating safety and pharmacokinetic study evaluated an oral suspension of micronized atovaquone (m-atovaquone) in infants and children stratified into age groups from 1 month to 12 years of age."( Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group.
Beauchamp, B; Dorenbaum, A; Hughes, W; McNamara, J; Moye, J; Purdue, L; Rogers, M; Sadler, B; van Dyke, R; Xu, J; Yogev, R, 1998
)
0.76
" Factors such as inter- and intraindividual pharmacokinetic variability and changes in AZT intracellular concentrations should be considered as other mechanisms responsible for changes in AZT pharmacokinetics with concomitant therapies."( Glucuronidation of 3'-azido-3'-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid.
Collins, JM; Jamis-Dow, C; Klecker, RW; Trapnell, CB, 1998
)
0.5
" Despite a lack of significant difference in the mean AZ pharmacokinetic parameters, the steady-state values of AZ's area under the concentration-time curve from 0 to 24 h and maximum concentration in serum were consistently lower (n = 7 of 7) for the SIM regimen than they were for the ALONE regimen."( Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team.
Burchett, S; Dankner, WM; Hughes, WT; Ngo, LY; Sadler, B; Unadkat, JD; Xu, J; Yogev, R, 1999
)
0.54
" The geometric mean elimination half-life (t1/2) of atovaquone was 57."( Lack of a pharmacokinetic interaction between atovaquone and proguanil.
Gillotin, C; Mamet, JP; Veronese, L, 1999
)
0.81
"To determine the pharmacokinetic profiles of atovaquone (ATO), proguanil (PROG) and its active metabolite cycloguanil (CYCLO) with respect to possible accumulation and kinetic interaction upon repeated dosing with Malarone."( Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis.
Ashton, M; Bergqvist, Y; Björkman, A; Johansson, I; Lindegårdh, N; Nivelius, S; Thapar, MM, 2002
)
0.82
" Single-dose and steady-state pharmacokinetic parameters were determined for each individual."( Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis.
Ashton, M; Bergqvist, Y; Björkman, A; Johansson, I; Lindegårdh, N; Nivelius, S; Thapar, MM, 2002
)
0.56
"To determine the pharmacokinetic properties of atovaquone, proguanil, and the triazine metabolite cycloguanil in women with recrudescent multi-drug resistant falciparum malaria during the second and third trimesters of pregnancy treated by artesunate-atovaquone-proguanil."( The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria.
Cho, T; Edstein, MD; Gilveray, G; Looareesuwan, S; McGready, R; Nosten, F; Stepniewska, K; White, NJ, 2003
)
0.88
" Using conventional and population pharmacokinetic analyses, Cl/F and Vd/F estimates for both drugs were approximately twice, and plasma concentrations less than half those reported previously in healthy subjects and patients with acute malaria."( The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria.
Cho, T; Edstein, MD; Gilveray, G; Looareesuwan, S; McGready, R; Nosten, F; Stepniewska, K; White, NJ, 2003
)
0.63
" The pharmacodynamic interactions among atovaquone, proguanil and its metabolite cycloguanil were investigated in 4 Plasmodium falciparum parasite strains by culture assays in vitro."( Pharmacodynamic interactions among atovaquone, proguanil and cycloguanil against Plasmodium falciparum in vitro.
Björkman, A; Gupta, S; Spindler, C; Thapar, MM; Wernsdorfer, WH,
)
0.68
" Blood samples were taken for pharmacokinetic investigations of atovaquone, proguanil, and cycloguanil up to 288 h (day 14) after the last dose."( The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.
Kioy, D; Konsil, J; Manyando, C; Miller, GB; Mulenga, M; Na-Bangchang, K; Ruengweerayut, R, 2005
)
0.83
" There were no significant differences in any of the pharmacokinetic parameters of atovaquone, proguanil or cycloguanil between patients from Thailand and Zambia."( The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.
Kioy, D; Konsil, J; Manyando, C; Miller, GB; Mulenga, M; Na-Bangchang, K; Ruengweerayut, R, 2005
)
0.81
"The pharmacokinetics of atovaquone and cycloguanil appeared to be influenced by the pregnancy status, resulting in an decrease in the Cmax and AUC of approximately twofold."( The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.
Kioy, D; Konsil, J; Manyando, C; Miller, GB; Mulenga, M; Na-Bangchang, K; Ruengweerayut, R, 2005
)
0.9
"To determine the pharmacokinetic properties of dihydroartemisinin (DHA) following oral artesunate treatment in women with recrudescent multi-drug resistant falciparum malaria, in the second and third trimesters of pregnancy."( Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria.
Cho, T; Gilveray, G; Looareesuwan, S; McGready, R; Nosten, F; Stepniewska, K; Ward, SA; White, NJ, 2006
)
0.33
" Conventional non-compartmental modelling and a population one-compartment pharmacokinetic model were applied to the data."( Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria.
Cho, T; Gilveray, G; Looareesuwan, S; McGready, R; Nosten, F; Stepniewska, K; Ward, SA; White, NJ, 2006
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Identified articles were included in the review if the study had at least one group that reported at least one pharmacokinetic parameter of interest in pregnant women."( Pharmacokinetics of antimalarials in pregnancy: a systematic review.
Ensom, MH; Wilby, KJ, 2011
)
0.37
" The objective of this study is to show the pharmacokinetic (PK) profile of intravenous artesunate (AS), which was manufactured under good manufacturing practice (GMP) conditions, in adults with uncomplicated falciparum malaria in Kenya."( Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study.
Hickman, MR; Li, Q; Melendez, V; Miller, SR; Ogutu, B; Otieno, W; Polhemus, M; Remich, S; Smith, B; Teja-Isavadharm, P; Weina, PJ, 2014
)
0.4
" Pharmacokinetic data were analysed with a compartmental analysis for AS and DHA."( Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study.
Hickman, MR; Li, Q; Melendez, V; Miller, SR; Ogutu, B; Otieno, W; Polhemus, M; Remich, S; Smith, B; Teja-Isavadharm, P; Weina, PJ, 2014
)
0.4
" The high mean peak concentration (Cmax) of AS was shown to be 28,558 ng/mL while the Cmax of DHA was determined to be 2,932 ng/mL."( Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study.
Hickman, MR; Li, Q; Melendez, V; Miller, SR; Ogutu, B; Otieno, W; Polhemus, M; Remich, S; Smith, B; Teja-Isavadharm, P; Weina, PJ, 2014
)
0.4
" Given the much longer half-life of DHA compared to the short half-life of AS, DHA also plays a significant role in treatment of severe malaria."( Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study.
Hickman, MR; Li, Q; Melendez, V; Miller, SR; Ogutu, B; Otieno, W; Polhemus, M; Remich, S; Smith, B; Teja-Isavadharm, P; Weina, PJ, 2014
)
0.4
" The pharmacokinetic limitation of the current therapy and multi-drug resistance has resulted in an urgent need to study the new antimalarial combinations with existing drugs."( Investigation of pre-clinical pharmacokinetic parameters of atovaquone nanosuspension prepared using a pH-based precipitation method and its pharmacodynamic properties in a novel artemisinin combination.
Apsingekar, M; Juvekar, S; Kathpalia, H; Mohanraj, K; Shidhaye, S, 2020
)
0.8
" Pharmacokinetic data and studies on drug-sparing AP regimens suggest this to be the case."( On the potential for discontinuing atovaquone-proguanil (AP) ad-hoc post-exposure and other abbreviated AP-regimens: Pharmacology, pharmacokinetics and perspectives.
Bache, EB; Borrmann, S; de Jong, HK; Grobusch, MP; Hanscheid, T; Schlagenhauf, P; Schnyder, JL; van Hest, RM,
)
0.41

Compound-Compound Interactions

Atovaquone (ATQ) was investigated in a SCID mouse model of Pneumocystis carinii pneumonia (PCP) Participants were randomized to receive chloroquine alone or combined with artesunate, azithromycin or atovaqone-proguanil for all episodes of uncomplicated malaria for one year. The same dose protected 100% of infected mice when administered in combination with non-protective doses of atovaquones or sulphadiazines.

ExcerptReferenceRelevance
"The prophylactic efficacies of atovaquone (ATQ) alone and in combination with azithromycin, clarithromycin, rifabutin, proguanil, PS-15, trimethoprim, co-trimoxazole, or dapsone were investigated in a SCID mouse model of Pneumocystis carinii pneumonia (PCP)."( Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice.
Comley, JC; Sterling, AM, 1995
)
0.98
"The efficacy of atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, and minocycline was examined in vitro and in a murine model of acute toxoplasmosis."( In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Derouin, F; Pudney, M; Romand, S, 1993
)
0.87
"The activity of atovaquone in the treatment of murine toxoplasmosis was greatly enhanced when administered in combination with pyrimethamine or sulfadiazine."( The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo, FG; Lin, T; Remington, JS, 1993
)
0.98
" To improve cure rates, atovaquone was administered in combination with other drugs with antimalarial activity."( Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.
Canfield, CJ; Hutchinson, DB; Kyle, DE; Looareesuwan, S; Viravan, C; Webster, HK, 1996
)
0.92
" Doses of each drug that were not effective in reducing inflammation in the brain of mice with toxoplasmic encephalitis when used alone were used in combination with a dose of rifabutin which was minimally effective."( Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo, FG; Remington, JS; Suzuki, Y, 1996
)
0.57
"The efficacy of rifabutin (RIFA) alone or in combination with atovaquone (ATO) was examined in vitro and in a murine model of acute toxoplasmosis."( In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
Della Bruna, C; Derouin, F; Farinotti, R; Romand, S, 1996
)
0.77
"Clinical studies have shown proguanil (PROG) combined with atovaquone (ATQ) to be an effective and safe antimalarial combination for the treatment of multidrug-resistant falciparum malaria."( Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro.
Edstein, MD; Kyle, DE; Looareesuwan, S; Rieckmann, KH; Wilairatana, P; Yeo, AE,
)
0.59
"The anticryptosporidial activity of four macrolides alone and in combination with other antimicrobial agents was investigated against ten clinical isolates of Cryptosporidium parvum recovered from stools of AIDS patients."( In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum.
Cirioni, O; Giacometti, A; Scalise, G, 1996
)
0.53
" Trovafloxacin, a new fluoroquinolone with potent activity against Toxoplasma gondii, was examined for potential synergistic activity when combined with other drugs used for treatment of human toxoplasmosis."( Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.
Araujo, FG; Khan, AA; Polzer, RJ; Remington, JS; Slifer, T, 1997
)
0.3
" The same dose protected 100% of infected mice when administered in combination with non-protective doses of atovaquone, clindamycin or sulphadiazine."( Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
Araujo, FG; Bryskier, A; Khan, AA; Remington, JS, 1998
)
0.51
"The efficacy of atovaquone (ATO) combined with clindamycin (CLI) against Toxoplasma gondii was examined in murine models of infection with a mouse-non-virulent (Me49) strain."( Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.
Bobić, B; Djurković-Djaković, O; Grujić, J; Milenković, V; Nikolić, A, 2002
)
1.04
" We conclude that atovaquone-proguanil shows no evidence of cardiotoxicity either alone or when combined with artesunate."( Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate.
Gupta, RK; Looareesuwan, S; Nosten, F; Paiphun, L; Slight, T; Van Vugt, M; White, NJ, 2005
)
0.92
"The effect of 16 alpha-acetoxy-26-hydroxycholest-4-ene-3,22-dione (SN-1) isolated from Solanum nudum Dunal (a Solanaceae traditionally used for treating fever in Colombia) on Plasmodium falciparum erythrocyte stages and its in vitro antiplasmodial activity when combined with the following conventional drugs was studied: chloroquine (CQ), amodiaquine (AQ), desethylamodiaquine (desethyl-AQ), quinine (QN), artemisinin (AR), atovaquone (ATV) and quinine (QN)."( Plasmodium falciparum: Solanum nudum SN-1 steroid antiplasmodial activity when combined with antimalarial drugs.
Blair, S; Deharo, E; Pabón, A, 2011
)
0.53
" Participants were randomized to receive chloroquine alone or combined with artesunate, azithromycin or atovaquone-proguanil for all episodes of uncomplicated malaria for one year."( A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria.
Dzinjalamala, FK; Laufer, MK; Laurens, MB; Masonga, R; Nyirenda, OM; Plowe, CV; Stokes-Riner, A; Taylor, TE; Thesing, PC, 2012
)
0.81

Bioavailability

Atovaquone is poorly absorbed in more than half of immunocompromised patients and its bioavailability varies between individuals. The high variability in atovaqu one bioavailability prompts the need for therapeutic drug monitoring, especially in pediatric patients.

ExcerptReferenceRelevance
" Initial studies in humans indicate that 566C80 is safe and has adequate bioavailability after oral administration."( A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome.
Davey, RT; Falloon, J; Feuerstein, I; Hughes, W; Kovacs, J; LaFon, S; Lancaster, D; O'Neill, D; Polis, M; Rogers, M, 1991
)
0.28
" The bioavailability of the high and low doses of atovaquone was similar."( Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum.
Canfield, CJ; Eaves, J; Hussein, Z; Hutchinson, DB, 1997
)
0.84
"To compare the relative bioavailability of a single atovaquone 750 mg suspension oral dose when administered in the fasting state, after a normal breakfast, and after an enteral nutrition supplement."( Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement.
Dall, LH; Freeman, CD; Klutman, NE; Lamp, KC; Strayer, AH, 1998
)
0.84
"This study has shown that the new atovaquone oral suspension also has significantly greater bioavailability when administered after food or a nutrition supplement that has a moderate fat content."( Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement.
Dall, LH; Freeman, CD; Klutman, NE; Lamp, KC; Strayer, AH, 1998
)
0.87
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" In the case of BCS class II drugs dissolution is rate-limiting to absorption, so the use of biorelevant dissolution tests can be used to predict differences in bioavailability among different formulations and dosing conditions."( In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs.
Dressman, JB; Reppas, C, 2000
)
0.31
" While atovaquone has potent in vitro activity against Toxoplasma gondii, it is poorly absorbed after oral administration and shows poor therapeutic efficacy against TE."( Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
Borner, K; Hahn, H; Kayser, O; Krause, K; Liesenfeld, O; Müller, RH; Schöler, N, 2001
)
2.21
" The liquid form offers better bioavailability and convenient dosing."( FDA approves new PCP drug. Food and Drug Administration.
, 1995
)
0.29
"Although prediction of the plasma profile of lipophilic drugs solely on the basis of in vitro data remains an ambitious target, this study shows that the plasma profile of a lipophilic drug can be predicted with appropriate in vitro dissolution data, provided that the absolute bioavailability of the drug is known and the drug has dissolution limited absorption."( Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration.
Dressman, JB; Nicolaides, E; Reppas, C; Symillides, M, 2001
)
0.31
"Exogenous surfactants are increasingly used to enhance the dispersion properties of lipid-based formulations of poorly water-soluble drugs, yet their possible effects on formulation digestion and oral bioavailability in-vivo are not well documented."( Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone.
Boyd, BJ; Charman, WN; Porter, CJ; Sek, L, 2006
)
0.53
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" We synthesized atovaquone nanosuspensions (ANSs) coated with poloxamer 188 (P188) and sodium dodecyl sulfate (SDS) to improve oral bioavailability and passage through the blood-brain barrier (BBB)."( SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.
Borner, K; Fitzner, R; Heimesaat, MM; Lachenmaier, S; Liesenfeld, O; Lohman, U; Mauludin, R; Mueller, RH; Shubar, HM, 2011
)
1.11
" Relative bioavailability of ATO when loaded in nanoparticles ranged from 52% (for ATO-HPCD NP) to 71% (for ATO-DMCD NP), whereas for the suspension control formulation the bioavailability was only about 30%."( Cyclodextrin/poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone.
Agüeros, M; Calvo, J; Irache, JM; Lavandera, JL, 2011
)
0.59
" Selected as a preclinical candidate, ELQ-300 has good oral bioavailability at efficacious doses in mice, is metabolically stable, and is highly active in blocking transmission in rodent models of malaria."( Quinolone-3-diarylethers: a new class of antimalarial drug.
Angulo-Barturen, I; Avery, VM; Bathurst, I; Burrows, JN; Charman, SA; Cross, RM; Delves, MJ; Duffy, S; Ferrer, S; Forquer, IP; Gamo, FJ; Guy, RK; Herreros, E; Jiménez-Díaz, MB; Kelly, JX; Kocken, CHM; Kyle, DE; LaCrue, AN; Li, Y; Manetsch, R; Marfurt, J; Mather, MW; Morrisey, JM; Mutka, T; Nilsen, A; Noviyanti, R; Price, RN; Riscoe, MK; Ryan, E; Saenz, FE; Sanz, LM; Sebayang, BF; Shackleford, DM; Siegl, P; Sinden, RE; Steuten, J; Vaidya, AB; White, KL; Winter, RW; Wirjanata, G; Zeeman, AM, 2013
)
0.39
"Emerging parasite resistance and poor oral bioavailability of anti-malarials are the two cardinal issues which hinder the clinical success of malaria chemotherapy."( Bioavailability enhancement of atovaquone using hot melt extrusion technology.
Borhade, V; Deshpande, V; Gokarna, V; Kate, L; Pathak, S; Patravale, V; Prabhu, P; Sharma, S, 2016
)
0.72
"Atovaquone is poorly absorbed in more than half of immunocompromised patients and its bioavailability varies between individuals."( Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii.
Beckerich, F; Cordonnier, C; Hulin, A; Khoudour, N; Lê, MP; Leclerc, M; Massias, L; Maury, S; Melica, G; Redjoul, R; Robin, C, 2017
)
2.2
" High dose and poor bioavailability are the main hurdles associated with atovaquone oral therapy."( Atovaquone oral bioavailability enhancement using electrospraying technology.
Darade, A; Pathak, S; Patravale, V; Sharma, S, 2018
)
2.16
" In this study, nanoemulsion of this drug was prepared with grape seed oil using spontaneous emulsification method to increase bioavailability and efficacy of atovaquone for treatment of toxoplasmosis."( Nanoemulsion of atovaquone as a promising approach for treatment of acute and chronic toxoplasmosis.
Amani, A; Azami, SJ; Faramarzi, MA; Keshavarz, H; Mahmoudi, M; Mohebali, M; Najafi-Taher, R; Shojaee, S, 2018
)
1.02
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Therefore, formulating ATQ into its supersaturated state through solid dispersion for bioavailability enhancement can be of great value."( Quantification of atovaquone from amorphous solid dispersion formulation using HPLC: An in vitro and ex vivo investigation.
Aminu, N; Chan, SY; Goh, CF; Teoh, XY, 2021
)
0.96
" The present study exploits atovaquone/albumin nanoparticles to improve bioavailability and tumor targeting of atovaquone, enhancing the efficacy of anti-PD-1 therapy by normalizing tumor hypoxia."( Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment.
Chen, L; Feng, C; Hou, P; Huang, C; Ji, M; Sui, M; Wang, S; Yang, Q; Zeng, Z; Zhou, X, 2021
)
2.36
" The bioavailability and safety of HSA-ATO NPs were assessed by animal experiments."( Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment.
Chen, L; Feng, C; Hou, P; Huang, C; Ji, M; Sui, M; Wang, S; Yang, Q; Zeng, Z; Zhou, X, 2021
)
2.06
" The high variability in atovaquone bioavailability prompts the need for therapeutic drug monitoring, especially in pediatric patients."( Liquid Chromatography-Tandem Mass Spectrometry-Based Therapeutic Monitoring of Plasma Atovaquone Concentrations in Pediatric Patients.
Devaraj, S; Horvath, TD, 2024
)
1.97

Dosage Studied

The mechanism of action, pharmacokinetics and pharmacodynamics, clinical efficacy, adverse effects, and dosage of atovaquone in the management of mild to moderate Pneumocystis carinii pneumonia (PCP) are reviewed. The aim of the present investigation was to explore hot melt extrusion (HME) as a solvent-free technique to enhance solubility and oral bioavailability.

ExcerptRelevanceReference
" In patients with mild to moderate PCP, a dosage of 750mg 3 times daily (administered in tablet form) has similar overall therapeutic efficacy (defined as clinical response without a treatment-limiting adverse event) to the conventional therapies oral cotrimoxazole (trimethoprim-sulfamethoxazole) and intravenous pentamidine, respectively."( Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.
Goa, KL; Spencer, CM, 1995
)
1.73
" The recurrences were successfully treated by increasing the dosage of Atovaquone to 4 x 750 mg/d and the addition of Trimethoprime/Sulfamethoxazol and Clindamycine/Pyrimethamine respectively."( [Treatment of toxoplasmosis retinochoroiditis with atovaquone in an AIDS patient].
Althaus, C; Armbrecht, C; Jablonowski, H; Schimkat, M; Sundmacher, R, 1995
)
0.78
" ATQ drug combinations affected the prophylactic efficacy of a subcurative dosage of ATQ (50 mg/kg/day given orally) in the following ways: dapsone (25 mg/kg/day) or co-trimoxazole (25 mg of sulfamethoxazole plus 5 mg of trimethoprim per kg/day) had no significant effect on ATQ, azithromycin (200 mg/kg/day) or clarithromycin (200 mg/kg/day) had a slight additive effect with ATQ, trimethoprim (100 mg/kg/day) or PS-15 (5 mg/kg/day) had an additive effect with ATQ, and proguanil (25 mg/kg/day) or rifabutin (200 mg/kg/day) had a marked synergistic effect on ATQ."( Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice.
Comley, JC; Sterling, AM, 1995
)
0.69
"The mechanism of action, pharmacokinetics and pharmacodynamics, clinical efficacy, adverse effects, and dosage of atovaquone in the management of mild to moderate Pneumocystis carinii pneumonia (PCP) are reviewed."( Atovaquone: a new antipneumocystis agent.
Artymowicz, RJ; James, VE, 1993
)
1.94
" At an oral dosage equivalent to 100 mg of ATQ per kg of body weight per day, 17C91 protected 9 of 10 mice from PCP and had a prophylactic efficacy comparable to that of co-trimoxazole (at 250 mg of sulfamethoxazole plus 50 mg of trimethoprim per kg per day orally)."( Antipneumocystis activity of 17C91, a prodrug of atovaquone.
Comley, JC; Frend, TJ; Yeates, CL, 1995
)
0.55
" These results suggest that combining rifabutin with certain drugs that are active against Toxoplasma gondii may be useful for the treatment of toxoplasmic encephalitis in humans and may allow for a reduction in dosage of either or both drugs with a resulting reduction in untoward side effects."( Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo, FG; Remington, JS; Suzuki, Y, 1996
)
0.57
"The single- and multiple-dose pharmacokinetics of and tolerability to a new microfluidized suspension of atovaquone were studied in human immunodeficiency virus-seropositive patients with CD4 counts of < or = 200 cells per mm3 in order to define a dosing regimen for the treatment of Pneumocystis carinii pneumonia."( Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients.
Dixon, R; Posner, J; Pozniak, AL; Rolan, P; Watt, HM, 1996
)
0.73
" The results of this preliminary study suggest that ATQ is unlikely to affect the pharmacokinetics of PROG to a clinically important extent at an ATQ dosage of 500 mg twice a day for 3 days in malaria infected patients."( Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone.
Edstein, MD; Kyle, DE; Looareesuwan, S; Viravan, C, 1996
)
0.52
" Dosages of 30 mg/kg/day were adequate to achieve an average steady-state concentration of greater than 15 micrograms/ml in children ages 1 to 3 months and 2 to 12 years, but a dosage of 45 mg/kg/day was needed to reach this concentration in infants 3 to 24 months of age."( Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group.
Beauchamp, B; Dorenbaum, A; Hughes, W; McNamara, J; Moye, J; Purdue, L; Rogers, M; Sadler, B; van Dyke, R; Xu, J; Yogev, R, 1998
)
0.55
" Dosing or frequency of TMP-SMX did not seem to influence risk of chemoprophylaxis failure."( Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators.
Holmberg, SD; Moorman, AC; Palella, FJ; Von Bargen, JC, 1998
)
0.3
" Nanocapsules were chosen as the oral dosage form of administration."( Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.
Aumjaud, Y; Derouin, F; Fessi, H; Sordet, F, 1998
)
0.59
" For the assay of proguanil, cycloguanil and atovaquone, blood was sampled before dosing and at regular intervals over 8 days when proguanil was given, and over 17 days when atovaquone was given."( Lack of a pharmacokinetic interaction between atovaquone and proguanil.
Gillotin, C; Mamet, JP; Veronese, L, 1999
)
0.82
" During a long-term dosing phase, a subset of subjects were evaluated for an interaction between atovaquone and trimethoprim-sulfamethoxazole (TMP-SMX)."( Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study.
Bechtel, C; Davey, RT; Falloon, J; Kovacs, JA; LaFon, SW; Lane, HC; Masur, H; Piscitelli, SC; Polis, MA; Sadler, B; Sargent, S; Walker, RE, 1999
)
1.96
" Differences between products (both in vitro or in vivo) were less pronounced than differences due to media composition (in vitro) or dosing conditions (in vivo)."( Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data.
Dressman, JB; Efthymiopoulos, C; Galia, E; Nicolaides, E; Reppas, C, 1999
)
0.3
" The dosing regimen was well tolerated."( Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand.
Chinnapha, S; Chulay, JD; Glanarongran, R; Indravijit, KA; Looareesuwan, S; Scott, TR; Supeeranontha, L; Wilairatana, P,
)
1.57
" It was not possible to obtain the ED(50) for free ATV because the dose-response curve reached a plateau around 33% of parasite suppression."( Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis.
Astier, A; Cauchetier, E; Deniau, M; Fessi, H; Paul, M; Rivollet, D, 2000
)
0.55
" In the case of BCS class II drugs dissolution is rate-limiting to absorption, so the use of biorelevant dissolution tests can be used to predict differences in bioavailability among different formulations and dosing conditions."( In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs.
Dressman, JB; Reppas, C, 2000
)
0.31
" Overall results from these studies indicate patients who are eligible for PCP prophylaxis should be advised to take double-strength trimethoprim/sulfamethoxazole (TMP/SMX) on a daily basis, a dosage found more effective than thrice-weekly."( Optimizing PCP therapy.
Cadman, J; Torres, G, 1997
)
0.3
" The latter is defined as regular intake of antimalarial drugs in subtherapeutic dosage in order to suppress the development of clinical disease."( [Malaria--chemoprophylaxis 2001].
Beck, B; Blum, J; Funk, M; Furrer, H; Genton, B; Hatz, FR; Holzer, B; Loutan, L; Markwalder, K; Raeber, PA; Schlagenhauf, P; Siegl, G; Steffen, R; Stürchler, D; Wyss, R, 2001
)
0.31
" Good safety, tolerance, and efficacy, along with key advantages in dosing requirements, make primaquine an excellent drug for preventing malaria in nonpregnant, G6PD-normal travelers."( Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia.
Baird, JK; Bangs, MJ; Barcus, MJ; Basri, H; Fryauff, DJ; Gramzinski, R; Hoffman, SL; Jones, TR; Kusumaningsih, M; Lacy, MD; Ling, J; Maguire, JD; Sismadi, P; Wiady, I, 2001
)
0.31
"To determine the pharmacokinetic profiles of atovaquone (ATO), proguanil (PROG) and its active metabolite cycloguanil (CYCLO) with respect to possible accumulation and kinetic interaction upon repeated dosing with Malarone."( Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis.
Ashton, M; Bergqvist, Y; Björkman, A; Johansson, I; Lindegårdh, N; Nivelius, S; Thapar, MM, 2002
)
0.82
" falciparum malaria in nonimmune adults, adolescents and children (>/=11 kg) visiting malaria-endemic regions for ( Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
McKeage, K; Scott, L, 2003
)
1.96
" falciparum malaria and compared with other commonly used antimalarial agents has an improved tolerability profile, and, overall, a more convenient dosage regimen, particularly in the post-travel period."( Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
McKeage, K; Scott, L, 2003
)
1.76
"The patient was given chloroquine by his captain in a dosage regimen appropriate for quinine (2 tablets 3 times daily for 7 d)."( Toxicity related to chloroquine treatment of resistant vivax malaria.
Barrett, PH; Davis, TM; Ilett, KF; Syed, DA, 2003
)
0.32
" For drugs with a narrow therapeutic index such as chloroquine, recommended dosing regimens should be respected, and adequate information sources must be available where such drugs are dispensed by untrained personnel."( Toxicity related to chloroquine treatment of resistant vivax malaria.
Barrett, PH; Davis, TM; Ilett, KF; Syed, DA, 2003
)
0.32
" The dose-response data indicated that livers would have been cleared of parasites if the nanocapsule preparation had been given as three doses each equivalent to 3 mg ATV/kg, whereas the maximum suppression possible with the free drug would have been about 61%, whatever the dose."( Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis.
Astier, A; Cauchetier, E; Deniau, M; Fessi, H; Paul, M; Rivollet, D, 2003
)
0.56
" Both have the advantage of providing causal prophylaxis and therefore require continued dosing for only 1 wk after departure from a malaria endemic area."( The impact of Malarone and primaquine on psychomotor performance.
Cook, T; Gibson, N; Gray, G; Kenny, G; McCarthy, AE; Paul, MA, 2003
)
0.32
"Twenty-eight subjects (20 men and 8 women) ranging from 21 to 52 yr of age were assessed for psychomotor performance on 2 psychomotor test batteries at the end of a 7-d dosing protocol for each of placebo, Malarone, and primaquine treatment, in a double-blind crossover design with counterbalanced treatment order."( The impact of Malarone and primaquine on psychomotor performance.
Cook, T; Gibson, N; Gray, G; Kenny, G; McCarthy, AE; Paul, MA, 2003
)
0.32
"A randomized, double-blind crossover study was conducted in which 24 subjects were enrolled to use A/P and placebo, each in a 14-day prophylactic dosing regimen with a 21-day washout phase."( Malaria prophylaxis for aircrew: safety of atovaquone/proguanil in healthy volunteers under aircraft cabin pressure conditions.
Krul, AJ; Simons, R; Valk, PJ,
)
0.39
" The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model."( Spiroindolones, a potent compound class for the treatment of malaria.
Beck, HP; Brun, R; Cohen, SB; Dartois, V; Dharia, NV; Diagana, TT; Fidock, DA; Goh, A; González-Páez, GE; Jegla, T; Keller, TH; Lakshminarayana, SB; Lee, MC; McNamara, C; Nosten, F; Plouffe, DM; Renia, L; Rottmann, M; Russell, B; Schmitt, EK; Seitz, P; Spencer, KR; Suwanarusk, R; Tan, J; Winzeler, EA; Yeung, BK; Zou, B, 2010
)
0.36
" One dose of warfarin was withheld and then the total weekly warfarin dosage was decreased by another 10%."( A potential interaction between warfarin and atovaquone.
Dean, SR; Hidalgo, K; Lyles, A, 2011
)
0.63
" Firstly, 1 mg mL(-1) of each drug in 20% 1,8-Cineole in ethanol was used; and secondly, 5 mg mL(-1) AT and 1 mg mL(-1) PR in 20% 1-methyl-2-pyrrolidone in ethanol was examined, dosed every 2 h over a 12-h period and receptor phase samples were analyzed by HPLC."( Delivery of atovaquone and proguanil across sublingual membranes, in vitro.
Heard, CM; Ong, CM; Wallace, E,
)
0.51
"We conducted a randomized, placebo-controlled, double-blind trial to establish the efficacy of atovaquone-proguanil to prevent malaria with the goal of simulating weekly dosing in a human Plasmodium falciparum challenge model."( Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.
Clemens, EG; Deye, GA; Dumler, JS; Fracisco, S; Macareo, L; Magill, AJ; Miller, L; Miller, RS; Murphy, J; Salas, CJ; Smith, BL; Sousa, JC; Tosh, D, 2012
)
0.85
" falciparum challenge at dosing intervals supportive of weekly dosing."( Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.
Clemens, EG; Deye, GA; Dumler, JS; Fracisco, S; Macareo, L; Magill, AJ; Miller, L; Miller, RS; Murphy, J; Salas, CJ; Smith, BL; Sousa, JC; Tosh, D, 2012
)
0.63
" Dosage adjustments based on body weight categories in children (1/4 dose for 11-20 kg, 1/2 dose for > 20-30 kg, 3/4 dose for > 30-40 kg, and full dose for > 40 kg) achieve plasma concentrations that are safe and effective during prophylaxis and treatment of malaria."( Clinical pharmacology of atovaquone and proguanil hydrochloride.
Beerahee, M, 1999
)
0.61
"The clinical pharmacology of atovaquone and proguanil provides a rationale for the dosing regimens recommended for treatment and prophylaxis of malaria."( Clinical pharmacology of atovaquone and proguanil hydrochloride.
Beerahee, M, 1999
)
0.9
" These options differ by dosing regimen, cost, and side effect profile."( Knowledge, attitudes, and practices regarding antimalarial chemoprophylaxis in U.S. Peace Corps Volunteers--Africa, 2013.
Arguin, PM; Landman, KZ; Tan, KR, 2014
)
0.4
"Twenty-nine subjects completed both dosing cohorts."( Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects.
Alfaro, RM; Calderón, MM; Kovacs, JA; Kumar, P; McManus, M; Pau, AK; Penzak, SR, 2016
)
0.68
" The aim of the present investigation was to explore hot melt extrusion (HME) as a solvent-free technique to enhance solubility and oral bioavailability of Atovaquone and to develop an oral dosage form for Atovaquone-Proguanil combination."( Bioavailability enhancement of atovaquone using hot melt extrusion technology.
Borhade, V; Deshpande, V; Gokarna, V; Kate, L; Pathak, S; Patravale, V; Prabhu, P; Sharma, S, 2016
)
0.92
" In our monotherapy assessments, we found that ATV functioned as a single-dose curative compound in suppressive tests whereas ELQ-300 demonstrated a unique cumulative dosing effect that successfully blocked recrudescence even in a high-parasitemia acute infection model."( Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria.
Forquer, IP; Kelly, JX; Li, Y; Morrisey, JM; Nilsen, A; Pou, S; Riscoe, MK; Smilkstein, MJ; Stickles, AM; Vaidya, AB; Winter, RW, 2016
)
1.88
"Current guidelines recommend daily dosing of atovaquone-proguanil (AP), beginning a day before travel to endemic areas and continuing for 7 days after departure."( Effectiveness of twice a week prophylaxis with atovaquone-proguanil (Malarone®) in long-term travellers to West Africa.
Bar-Meir, M; Eisenberg, N; Lachish, T; Schwartz, E, 2016
)
0.95
" It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg."( Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
Berry, P; Campo, B; Cao, J; Ciaravino, V; Easom, EE; Erve, JCL; Freund, YR; Gamo, FJ; Guo, D; Jacobs, RT; Plattner, JJ; Rosenthal, PJ; Sanz, LM; Zhang, YK, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxy-1,2-naphthoquinoneAny member of the class of 1,2-naphthoquinones in which the naphthoquinone moiety is substituted by at least one hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (55)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency15.84890.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency10.41550.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency15.08900.173734.304761.8120AID1346924
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
SMAD family member 3Homo sapiens (human)Potency15.08900.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency4.41200.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency16.78550.000714.592883.7951AID1259369
Microtubule-associated protein tauHomo sapiens (human)Potency10.00000.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency12.35160.000221.22318,912.5098AID1259243; AID1259247; AID743036; AID743053
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency6.30960.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.98110.001318.074339.8107AID926; AID938
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency2.51190.01237.983543.2770AID1346984
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.84850.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency11.23330.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency13.33320.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency11.27000.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency14.14560.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency2.66010.001019.414170.9645AID743191
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency5.16250.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency3.23870.000723.06741,258.9301AID743085; AID743122
activating transcription factor 6Homo sapiens (human)Potency2.39140.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency12.71690.057821.109761.2679AID1159526; AID1159528
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency12.58930.316212.443531.6228AID924
cytochrome P450 2C9 precursorHomo sapiens (human)Potency1.99530.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency39.81070.001815.663839.8107AID894
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency5.01190.794321.275750.1187AID624246
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency7.16690.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency33.48890.042027.378961.6448AID743210
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency10.00000.65619.452025.1189AID927
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency6.68190.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency5.75060.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency0.55450.004611.374133.4983AID624296; AID624297
VprHuman immunodeficiency virus 1Potency14.12541.584919.626463.0957AID651644
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency15.47190.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency0.06310.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency6.30960.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency26.60320.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency1.83760.002319.595674.0614AID651631; AID720552
Integrin beta-3Homo sapiens (human)Potency12.58930.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency12.58930.316211.415731.6228AID924
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency26.60320.001551.739315,848.9004AID1259244
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency1.99530.00638.235039.8107AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.89130.009610.525035.4813AID1479145
Guanine nucleotide-binding protein GHomo sapiens (human)Potency5.62341.995325.532750.1187AID624288
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency10.00001.584913.004325.1189AID927
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydroorotate dehydrogenase Schistosoma mansoniIC50 (µMol)0.43100.01901.94088.8000AID1592257; AID1604306
Cytochrome bHomo sapiens (human)IC50 (µMol)2.83500.00502.75488.0920AID1801889
Dihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)IC50 (µMol)8.57500.00050.742710.0000AID1592258; AID1604292; AID1657900; AID729494
Dihydroorotate dehydrogenase Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)10.00000.23002.64439.4800AID370979
Dihydroorotate dehydrogenase Plasmodium falciparum (malaria parasite P. falciparum)Ki27.00000.03000.03000.0300AID729492
Dihydroorotate dehydrogenase (quinone), mitochondrialRattus norvegicus (Norway rat)IC50 (µMol)0.70000.00900.14100.7000AID729493
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)0.23000.00401.966610.0000AID1873204
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)Kic2.70002.70002.70002.7000AID729496
Dihydroorotate dehydrogenase (quinone), mitochondrialRattus norvegicus (Norway rat)Kic0.06000.06000.06000.0600AID729495
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (277)

Processvia Protein(s)Taxonomy
response to hypoxiaCytochrome bHomo sapiens (human)
mitochondrial electron transport, ubiquinol to cytochrome cCytochrome bHomo sapiens (human)
response to xenobiotic stimulusCytochrome bHomo sapiens (human)
response to toxic substanceCytochrome bHomo sapiens (human)
electron transport coupled proton transportCytochrome bHomo sapiens (human)
animal organ regenerationCytochrome bHomo sapiens (human)
response to cobalaminCytochrome bHomo sapiens (human)
response to glucagonCytochrome bHomo sapiens (human)
cellular respirationCytochrome bHomo sapiens (human)
response to ethanolCytochrome bHomo sapiens (human)
response to cadmium ionCytochrome bHomo sapiens (human)
response to copper ionCytochrome bHomo sapiens (human)
response to mercury ionCytochrome bHomo sapiens (human)
response to calcium ionCytochrome bHomo sapiens (human)
response to hyperoxiaCytochrome bHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
UDP biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
'de novo' UMP biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
pyrimidine ribonucleotide biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (86)

Processvia Protein(s)Taxonomy
ubiquinol-cytochrome-c reductase activityCytochrome bHomo sapiens (human)
protein-containing complex bindingCytochrome bHomo sapiens (human)
metal ion bindingCytochrome bHomo sapiens (human)
ubiquinol-cytochrome-c reductase activityCytochrome bHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
dihydroorotase activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
protein bindingDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
dihydroorotate dehydrogenase (quinone) activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
dihydroorotate dehydrogenase activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (62)

Processvia Protein(s)Taxonomy
mitochondrionCytochrome bHomo sapiens (human)
mitochondrial inner membraneCytochrome bHomo sapiens (human)
mitochondrial respiratory chain complex IIICytochrome bHomo sapiens (human)
membraneCytochrome bHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
nucleoplasmDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrionDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrial inner membraneDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
cytosolDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrial inner membraneDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (481)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID28981Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1140157Inhibition of human cytochrome bc1 complex derived from HEK293 cell mitochondria using 50 uM decylubiquinol as substrate2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID1771305Antiplasmodial activity against Plasmodium falciparum 3D7 infected in human erythrocyte assessed as intraerythrocytic growth inhibition incubated for 72 hrs by DAPI-staining based imaging analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID510926Antimalarial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID663124Antimalarial activity against Plasmodium berghei NS infected in po dosed CD1 mouse assessed as decrease in parasitemia measured on day 42012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
AID1649415Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for multidrug resistant Plasmodium falciparum D6 infected in human erythrocytes2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID495508Antimicrobial activity against Toxoplasma gondii type 2 ME49 strain orally infected in ip dosed IRF-8 deficient mouse brain assessed as decrease in inflammatory foci administered for 5 days after 3 days post 28 day 400 mg/dl sulfadiazine dosing by quantit2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii.
AID641577Antimalarial activity against chloroquine-, pyrimethamine-resistant ring stage Plasmodium falciparum W2 infected in human A positive erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones.
AID1657901Competitive inhibition of Plasmodium falciparum DHODH2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Bifunctional Naphtho[2,3-
AID599525Growth inhibition of human DU145 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Atovaquone derivatives as potent cytotoxic and apoptosis inducing agents.
AID1810599Antiplasmodial activity against asexual blood stage of multidrug-resistant Plasmodium falciparum TM90C2B infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by SYBR green 1 staining based assay
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID157839In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF542000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Phenyl beta-methoxyacrylates: a new antimalarial pharmacophore.
AID1155471Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID1649414Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID704273Antimalarial activity against multidrug-resistant Plasmodium falciparum TM90-C2B infected in O-positive erythrocytes assessed as reduction in parasitemia after 72 hrs by spectrofluorometry2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.
AID529906Antimicrobial activity against Plasmodium falciparum harboring Y268S mutant Cytb gene, K1 allele group of msp1, 3D7 allele group of msp2 gene and 94 bp of 7A11, 196bp of C4M79 and 336bp of C4M69 locus measured on day 232008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
AID704268Cytotoxicity against human HEK293 cells after 72 hrs by luminescence analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID519618Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1160942Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in Balb/c mouse assessed as inhibition of parasitemia at 50 mg/kg administered as single dose on day 1 of infection measured on day 6 post exposure relative to control2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID748225Binding affinity to hematin (unknown origin) by UV-visible titration analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.
AID341602Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C42007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID422233Antiplasmodial activity after 48 hrs against Plasmodium falciparum W2 by [3H]hypoxanthine uptake2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Diterpene formamides from the tropical marine sponge Cymbastela hooperi and their antimalarial activity in vitro.
AID704265Cytotoxicity against human Raji cells after 72 hrs by luminescence analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.
AID1457212Antimalarial activity against Plasmodium falciparum V1/S infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1140154Antimalarial activity against multidrug-resistant Plasmodium falciparum Dd2 MRA-156 infected in human red blood cells assessed as suppression of parasitemia after 72 hrs by SYBR Green I-based fluorescence method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID663108Antimalarial activity against atoquinone-resistant Plasmodium falciparum TM90C2B2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
AID519623Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1192798Antimalarial activity against drug-sensitive Plasmodium falciparum NF54 by SYBR green-based assay2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Synthesis and in vitro evaluation of novel 8-aminoquinoline-pyrazolopyrimidine hybrids as potent antimalarial agents.
AID663112Antimalarial activity against Plasmodium berghei infected in CD1 mouse assessed as decrease in parasitemia at 20 mg/kg, po administered using Na2CO3 vehicle measured on day 4 relative to control2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
AID1140156Cytotoxicity against human HepG2 cells after 24 hrs incubation by Alamar Blue assay2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1125280Antimicrobial activity against blood-stage Plasmodium falciparum 3D7 assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs by liquid scintillation counting2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP).
AID519625Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID517479Resistant index. ratio of EC50 for chloroquine, mefloquine, pyrimethamine and atovaquone-resistant Plasmodium falciparum TM90-C2B to EC50 for chloroquine and pyrimethamine-resistant Plasmodium falciparum W22010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID1676944Antiplasmodial activity against late trophozoite synchronized chloroquine-resistant Plasmodium falciparum Dd2 reduction in microbial growth at 6.6 nM measured after 12 hrs by YOYO-1 staining-based flow cytometric analysis2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Synthesis, Structure-Activity Relationship, and Antimalarial Efficacy of 6-Chloro-2-arylvinylquinolines.
AID1676948Parasiticidal activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in RBC assessed as reduction in parasitemia at 6.6 nM incubated for 48 hrs followed by compound washout and then incubated for 96 hrs by Giemsa staining based microsco2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Synthesis, Structure-Activity Relationship, and Antimalarial Efficacy of 6-Chloro-2-arylvinylquinolines.
AID558827Antimalarial activity against Plasmodium falciparum W2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1190840Antiplasmodial activity against Plasmodium falciparum NF54 by SYBR Green-based method2015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
Synthesis and biological evaluation of adamantane-based aminophenols as a novel class of antiplasmodial agents.
AID358598Antiparasitic activity against Toxoplasma gondii RH infected in mouse L929 cells assessed as [3H]uracil incorporation at 1 uM after 72 hrs by scintillation counting2001Journal of natural products, Nov, Volume: 64, Issue:11
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
AID1155337Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for exo-erythrocytic form of Plasmodium berghei2014European journal of medicinal chemistry, Jul-23, Volume: 82Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID519626Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1593254Antimalarial activity against multidrug-resistant Plasmodium falciparum 7G8 infected in human erythrocytes by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1155422Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID18608Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1140163Inhibition of cytochrome bc1 complex isolated from trophozoite stage Plasmodium falciparum2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID1858878Antimalarial activity against Plasmodium berghei2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID300709Antiparasitic activity against Toxoplasma gondii tachyzoites m2m3 infected HFF cells2007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation.
AID1160928Antimalarial activity against multi-drug-resistant Plasmodium falciparum TM90-C2B infected in human type A+ erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I assay2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID601644Plasma protein binding in human by albumin chromatographic method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1649413Antimalarial activity against multidrug resistant Plasmodium falciparum Tm90-C2B infected in human erythrocytes measured after after 72 hrs by SYBR green dye based fluorescence assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID158849Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
Structure-activity relationships of novel anti-malarial agents. Part 2: cinnamic acid derivatives.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID422232Antiplasmodial activity after 48 hrs against Plasmodium falciparum FCR3F86 by [3H]hypoxanthine uptake2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Diterpene formamides from the tropical marine sponge Cymbastela hooperi and their antimalarial activity in vitro.
AID1649411Antimalarial activity against multidrug resistant Plasmodium falciparum Dd2 infected in human erythrocytes measured after after 72 hrs by SYBR green dye based fluorescence assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID1337666Antiplasmodial activity against chloroquine/pyrimethamine/proguanil-resistant Plasmodium falciparum K1 infected in human erythrocytes after 72 hrs by SYBR Green 1 dye based fluorescence spectrophotometric method2017European journal of medicinal chemistry, Jan-05, Volume: 125Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold.
AID341605Antimicrobial activity against Giardia duodenalis G12007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID704271Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in O-positive erythrocytes assessed as reduction in parasitemia after 72 hrs by spectrofluorometry2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.
AID1240753Antimalarial activity against Plasmodium falciparum infected in erythrocytes assessed as young trophozoites level at antimalarial IC50 level incubated for 24 and 48 hrs by Giemsa staining based microsocpy2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials.
AID1770444Selectivity index, ratio of CC50 for cytotoxicity against human HepG2 cells to EC50 for antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 infected in human erythrocytes2021European journal of medicinal chemistry, Nov-15, Volume: 224Antiplasmodial 2-thiophenoxy-3-trichloromethyl quinoxalines target the apicoplast of Plasmodium falciparum.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID384960Antimalarial activity against Plasmodium falciparum 3D7A infected erythrocytes by [3H]hypoxanthine uptake2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.
AID1626159Antimalarial activity against GFP expressing Plasmodium berghei infected in mouse assessed as inhibition of parasitemia at 10 mg/kg, po administered on days 3, 4 and 5 and measured on day 6 post drug exposure by Giemsa staining based modified Thompson tes2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.
AID1743688Inhibition of mammosphere formation in human MCF7 cells incubated for 5 days2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
AID1533161Antimalarial activity against chloroquine-resistant Plasmodium falciparum TM90C2B harboring Y268S mutant measured after 48 hrs by SYBR green1 dye based fluorescence assay2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Potent Antimalarial 2-Pyrazolyl Quinolone
AID1489619Antimalarial activity against blood stage form of Plasmodium berghei infected in mouse assessed as inhibition of parasitemia at 50 mg/kg, po administered on day 1 post infection measured on day 3 by scouting assay relative to control2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.
AID527263Antimalarial activity against liver stages of Plasmodium yoelii expressing GFP infected in human HepG2:CD81 cells after 43 hrs by flow cytometry2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1541854Antimalarial activity against Plasmodium falciparum NF54 incubated for 48 hrs by [3H]-hypoxanthine incorporation assay
AID90977Percentage growth inhibition of Toxoplasma gondii at concentration of 2 ug/mL using an human myelomonocytic cell line THP-12000Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9
Quinonic derivatives active against a virulent strain of Toxoplasma gondii. Synthesis of 2-methylfuro[2,3-g]- and [3,2-g]isoquinolinetriones.
AID341603Antileishmanial activity against Leishmania donovani MHOM-ET-67/L82 amastigotes by axenic assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID776315Antiparasitic activity against Toxoplasma gondii tachyzoites by fluorescence assay2013European journal of medicinal chemistry, Nov, Volume: 69Design, synthesis and biological evaluation of WC-9 analogs as antiparasitic agents.
AID1541831Antimalarial activity against asexual stage of Plasmodium falciparum Dd2 infected in erythrocytes assessed as reduction in parasite growth incubated for 48 hrs under hypoxic condition by Hoechst 33342 staining based flow cytometry
AID1403757Selectivity index, CC50 for human HepG2 cells to IC50 for chloroquine-resistant/mefloquine-sensitive Plasmodium falciparum W2 ring stage forms2018European journal of medicinal chemistry, Feb-10, Volume: 145Antimalarial naphthoquinones. Synthesis via click chemistry, in vitro activity, docking to PfDHODH and SAR of lapachol-based compounds.
AID663123Antimalarial activity against Plasmodium berghei NS infected in CD1 mouse assessed as decrease in parasitemia at 20 mg/kg, po administered using SSV as vehicle measured on day 42012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
AID1541856Antimalarial activity against Plasmodium falciparum TM90C2B incubated for 48 hrs by [3H]-hypoxanthine incorporation assay
AID1243885Antiplasmodial activity against blood stage of chloroquine-sensitive Plasmodium falciparum NF54 by parasite lactate dehydrogenase assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Primaquine-pyrimidine hybrids: synthesis and dual-stage antiplasmodial activity.
AID1489616Cytotoxicity against mouse J774 cells after 72 hrs by CellTiter-96 aqueous one solution cell proliferation assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.
AID558828Antimalarial activity against Plasmodium falciparum D6 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID772515Antimalarial activity against gametocytic stage of Plasmodium berghei infected in blood assessed as inhibition of ookinete formation at 10 uM after 24 hrs by Giemsa staining-based microscopic analysis relative to control2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID558829Antimalarial activity against Plasmodium falciparum FCM29 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID607827Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 48 hrs using Hema 3 staining by microscopic analysis2011Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15
Synthesis and biological activities of 4-N-(anilinyl-n-[oxazolyl])-7-chloroquinolines (n=3' or 4') against Plasmodium falciparum in in vitro models.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID370982Antimalarial activity against Plasmodium falciparum DD2 expressing Saccharomyces cerevisiae DHOD by [3H]hypoxanthine uptake2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.
AID1457213Antimalarial activity against Plasmodium falciparum 7G8 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting 2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1355304Plasmodicidal activity against Plasmodium falciparum 3D7A infected in erythrocytes assessed as parasite survival at 10 times IC50 pre-incubated for 48 hrs followed by compound washout and measured after 24 hrs by 1H-hypoxanthine incorporation assay (Rvb =2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Discovery of Marinoquinolines as Potent and Fast-Acting Plasmodium falciparum Inhibitors with in Vivo Activity.
AID1489620Antimalarial activity against blood stage form of Plasmodium berghei infected in mouse assessed as inhibition of parasitemia at 50 mg/kg, po administered on day 1 post infection measured on day 6 by scouting assay relative to control2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.
AID1676767Antiplasmodial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as induction of parasite killing at 10 times IC50 incubated up to 24 hrs followed by media replenishment with fresh drug and further incubated for 48 hrs by 2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Synthesis and Structure-Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-
AID1229890Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 cultured in human erythrocytes incubated for 48 hrs by [3H]-hypoxanthine incorporation assay2015Journal of medicinal chemistry, Jul-09, Volume: 58, Issue:13
Benzoxaborole antimalarial agents. Part 4. Discovery of potent 6-(2-(alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles.
AID1533164Inhibition of recombinant Plasmodium falciparum NDH2 expressed in Escherichia coli using NADH as substrate2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Potent Antimalarial 2-Pyrazolyl Quinolone
AID558845Antimalarial activity against Plasmodium falciparum IMT K4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID685500HARVARD: Cytotoxicity in HepG2 cell line2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID1649423Antimalarial activity against luciferase-expressing Plasmodium berghei ANKA 676m1cl1 sporozoites infected in human HepG2A16 cells measured after 45 hrs by luciferase-luciferin based reporter gene assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID1337667Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold.
AID104331Effective dose was determined in vivo for 90% parasite (Plasmodium berghei) reduction in the male albino mice after subcutaneous administration2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Phenyl beta-methoxyacrylates: a new antimalarial pharmacophore.
AID1155423Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID1604292Inhibition of human DHODH2019European journal of medicinal chemistry, Dec-01, Volume: 183Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.
AID558834Antimalarial activity against Plasmodium falciparum IMT Bres assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1676766Antiplasmodial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as induction of parasite killing at 10 times IC50 incubated for 24 to 48 hrs followed by media replenishment with fresh drug and further incubated for 48 hrs2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Synthesis and Structure-Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-
AID1586956Antiplasmodial activity against chloroquine/proguanil/pyrimethamine-resistant synchronized stage of Plasmodium falciparum K1 after 72 hrs by SYBR green1 staining based spectrophotometric method2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Nongenotoxic 3-Nitroimidazo[1,2-
AID519624Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID517482Cytotoxicity index, ratio of EC50 for mice (Mus musculus) J774 cells to EC50 for chloroquine, mefloquine, pyrimethamine and atovaquone-resistant Plasmodium falciparum TM90-C2B2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID1160927Antimalarial activity against multi-drug-resistant Plasmodium falciparum W2 infected in human type A+ erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I assay2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID1810291Antimalarial activity against chloroquine and pyrimethamine resistant Plasmodium falciparum W2 infected in human erythrocytes assessed as reduction in parasite growth incubated for 48 hrs followed by addition of [3H]-hypoxanthine and measured after 24 hrs2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1
AID772517Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Using genetic methods to define the targets of compounds with antimalarial activity.
AID519608Selectivity index, ratio of TC50 for hepatocytes to IC50 for Plasmodium yoelii 2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID558836Antimalarial activity against Plasmodium falciparum IMT A4 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1457214Antimalarial activity against Plasmodium falciparum D6 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting m2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1894272Antiplasmodial activity against Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 48 hrs by 3H-hypoxanthine incorporation assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in
AID519607Cytotoxicity against Hepatocyte cells assessed as cell viability by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID279383Growth inhibition of Plasmodium falciparum ring stage in infected erythrocytes by DAPI growth assay2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID370981Antimalarial activity against Plasmodium falciparum DD2 by [3H]hypoxanthine uptake2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.
AID1592262Mixed-type inhibition of Schistosoma mansoni DHODH using DHO as substrate measured at 4 secs interval for 60 secs by Lineweaver-Burk plot analysis2019European journal of medicinal chemistry, Apr-01, Volume: 167Ligand-based design, synthesis and biochemical evaluation of potent and selective inhibitors of Schistosoma mansoni dihydroorotate dehydrogenase.
AID1541832Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 infected in erythrocytes assessed as reduction in parasite growth incubated for 48 hrs under hypoxic condition by Hoechst 33342 staining based flow cytometry
AID712443Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human erythrocytes assessed as reduction in parasitemia after 48 hrs by flow cytometry analysis2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
1,4-naphthoquinone cations as antiplasmodial agents: hydroxy-, acyloxy-, and alkoxy-substituted analogues.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1592252Inhibition of Schistosoma mansoni DHODH assessed as remaining enzyme activity at 500 uM using DHO as substrate measured at 4 secs interval for 60 secs by DCIP reduction based indirect assay relative to control2019European journal of medicinal chemistry, Apr-01, Volume: 167Ligand-based design, synthesis and biochemical evaluation of potent and selective inhibitors of Schistosoma mansoni dihydroorotate dehydrogenase.
AID1160941Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in Balb/c mouse assessed as inhibition of parasitemia at 50 mg/kg administered as single dose on day 1 of infection measured on day 3 post exposure relative to control2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID1587114Plasmodicidal activity against Plasmodium falciparum 3D7A infected in CFDA-SE-labelled erythrocytes assessed as parasite killing at 10 times EC50 treated for 24 to 48 hrs following media refreshment for every 24 hrs by FACS analysis2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Synthesis, Profiling, and in Vivo Evaluation of Cyclopeptides Containing
AID1810597Antiplasmodial activity against asexual blood stage of multidrug-resistant Plasmodium falciparum Dd2 infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by SYBR green 1 staining based assay
AID1421920Antiplasmodial activity against exo-erythrocytic stage of GFP-Luc-fused Plasmodium berghei ANKA infected in human HepG2 cells after 48 hrs by bioluminescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1541855Antimalarial activity against Plasmodium falciparum K1 incubated for 48 hrs by [3H]-hypoxanthine incorporation assay
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1649432Antimalarial activity against Plasmodium falciparum clinical isolates measured after 72 hrs by SYBR green dye based fluorescence assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID472367Antimalarial activity against Plasmodium falciparum Nigerian assessed as [3H]hypoxanthine uptake after 48 hrs by liquid scintillation counting2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and antimalarial activity of new atovaquone derivatives.
AID663110Antimalarial activity against Plasmodium berghei infected in CD1 mouse assessed as decrease in parasitemia at 20 mg/kg, po administered using standard suspension vehicle measured on day 4 relative to control2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
AID1604307Selectivity index, ratio of IC50 for human DHODH to IC50 for Schistosoma mansoni DHODH2019European journal of medicinal chemistry, Dec-01, Volume: 183Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.
AID1770443Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Antiplasmodial 2-thiophenoxy-3-trichloromethyl quinoxalines target the apicoplast of Plasmodium falciparum.
AID644042Antimalarial activity against ring stage Plasmodium falciparum 3D7 infected in human erythrocytes after 48 hrs by flow cytometry2012Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3
Benzoxaborole antimalarial agents. Part 2: Discovery of fluoro-substituted 7-(2-carboxyethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles.
AID285481Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 asexual gametocytes2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID495506Antimicrobial activity against GFP-expressing Toxoplasma gondii type 1 RH strain ip infected in NMRI mouse assessed as decrease in parasite DNA level in lungs at 32 mg/kg, ip administered 3 days postinfection for 5 days by quantitative PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii.
AID1833152Anti-bradyzoite activity against Toxoplasma gondii ESG reporter stain infected in NHDF cells assessed as parasite proliferation at 10 uM measured after 30 days by optical microscopic analysis2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1416034Binding affinity to recombinant Mycobacterium tuberculosis Rv1284 expressed in Escherichia coli BL21-Al cells assessed as change in melting temperature by SYPRO Orange dye based differential scanning fluorimetric method2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID729492Inhibition of plasmodium falciparum DHODH assessed as inhibition of [14C]bicarbonate incorporation into pyrimidine nucleotide by HPLC analysis2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
On dihydroorotate dehydrogenases and their inhibitors and uses.
AID685501HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID1247015Selectivity index, ratio of EC50 for human HepG2A16 cells to EC50 for chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocyte2015European journal of medicinal chemistry, Sep-18, Volume: 102Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.
AID1125284Antimicrobial activity against Plasmodium berghei sporozoites infected in 12 hrs compound pretreated human HepG2 cells assessed as reduction in viability of exoerythrocytic forms measured after 48 hrs of incubation by luciferase bioluminescence assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP).
AID1201528Cytotoxicity against human HepG2 cells expressing CD81 assessed as cell viability after 72 hrs by CellTiter-glo assay2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
AID1243886Antiplasmodial activity against liver-stage of Plasmodium berghei expressing firefly luciferase infected in human Huh-7 cells after 48 hrs by bioluminescence assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Primaquine-pyrimidine hybrids: synthesis and dual-stage antiplasmodial activity.
AID510928Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone2 bearing P-type ATPase4 T418N and P990R mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID1201515Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for chloroquine-sensitive Plasmodium falciparum K1 infected in human erythrocytes2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
AID1182789Antiplasmodial activity against Plasmodium falciparum 7G8 harboring mutations conferring drug-resistance by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID624650Inhibition of AZT (0.02 mM) glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1457220Antimalarial activity against intraerythrocytic stage of Plasmodium falciparum assessed as parasite reduction ratio at 10 times IC50 preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting method2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID748221Inhibition of Cytochrome b-c1 complex in Plasmodium falciparum 3D7A mitochondria assessed as antimycin-sensitive decylubiquinol-cytochrome c oxidoreductase level2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.
AID1625267Antimalarial activity against blood stage Plasmodium yoelii infected in mouse administered qd through oral gavage for 4 days2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID1733034Antimalarial activity against artemisinin-sensitive Plasmodium falciparum F32-TEM by SYBR green dye based fluorescence assay2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID656213Antiplasmodial activity against Plasmodium falciparum W2 infected in human erythrocytes2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Phosphonium lipocations as antiparasitic agents.
AID1457222Antimalarial activity against intraerythrocytic stage of Plasmodium falciparum assessed as time required to clear 99.9% of initial parasite population at 10 times IC50 preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1140155Antimalarial activity against atovaquone-resistant clinical isolate Plasmodium falciparum TM90-C2B infected in human red blood cells assessed as suppression of parasitemia after 72 hrs by SYBR Green I-based fluorescence method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1457209Antimalarial activity against Plasmodium falciparum TM90C2A infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation count2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1833115Anti-tachyzoite activity against RFP-expressing Toxoplasma gondii RH Type 1 infected in NHDF cells assessed as destruction of host cells at 1 uM incubated for 96 hrs followed by removal of medium containing compounds and subsequent addition of fresh mediu2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID519606Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID519617Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1756035Antiplasmodial activity against asexual Plasmodium falciparum 3D7 infected in human erythrocytes assessed as reduction in parasitemia measured after 72 hrs by LDH assay2021Journal of natural products, 01-22, Volume: 84, Issue:1
Isolation, Structure Determination, and Total Synthesis of Hoshinoamide C, an Antiparasitic Lipopeptide from the Marine Cyanobacterium
AID1403755Antimalarial activity against chloroquine-resistant/mefloquine-sensitive Plasmodium falciparum W2 ring stage forms infected in human erythrocytes assessed as reduction in parasite growth after 48 hrs by parasite LDH release assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Antimalarial naphthoquinones. Synthesis via click chemistry, in vitro activity, docking to PfDHODH and SAR of lapachol-based compounds.
AID1436318Antimalarial activity against intraerythrocytic stage of Plasmodium falciparum 3D7A assessed as log (viable parasites +1) at 10 times IC50 after 24 hrs by [3H]-hypoxanthine incorporation assay (Rvb = 5 No_unit)2017European journal of medicinal chemistry, Jan-27, Volume: 126Novel inhibitors of Plasmodium falciparum based on 2,5-disubstituted furans.
AID510927Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone1 bearing P-type ATPase4 I398F and P990R mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID1391369Therapeutic index, ratio of TD50 for HFF to IC50 for tachyzoite stage of Toxoplasma gondii expressing beta-gal infected in HFF2018Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9
One-pot, multicomponent synthesis of 2,3-disubstituted quinazolin-ones with potent and selective activity against Toxoplasma gondii.
AID341604Antimicrobial activity against Giardia duodenalis WB2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1733038Antimalarial activity against ring stage artemisinin-resistant Plasmodium falciparum F32-ART5 assessed as time taken for recrudescence by measuring parasitemia at 7 uM after 48 hrs2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID1457208Antimalarial activity against Plasmodium falciparum HB3 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting 2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID558843Antimalarial activity against Plasmodium falciparum IMT K14 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1155473Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID606571Antimalarial activity against chloroquine, mefloquine, pyrimethamine and atovaquone-resistant Plasmodium falciparum TM90-C2B infected in human A positive erythrocytes after 72 hrs by SYBR Green I assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.
AID1626160Antimalarial activity against GFP expressing Plasmodium berghei infected in mouse assessed as average time for mouse death at 10 mg/kg, po administered on days 3, 4 and 5 and measured on day 6 post drug exposure by Giemsa staining based modified Thompson 2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.
AID748228Antiplasmodial activity against liver stage Plasmodium berghei infected in human HuH7 cells co-expressing GFP-Luccon treated for 1 hr prior to infection followed by 24 hrs after compound washout measured after 48 hrs post-infection by Alamar Blue assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.
AID1593256Cytotoxicity against human HepG2 cells measured after 24 to 36 hrs by resazurin dye based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1833142Anti-tachyzoite activity against RFP-expressing Toxoplasma gondii RH Type 1 infected in NHDF cells assessed as inhibition of plaque formation at 10 uM incubated for 96 hrs followed by removal of medium containing compounds and subsequent addition of fresh2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID729495Competitive inhibition of rat purified recombinant DHODH in presence of cofactor ubiquinone2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
On dihydroorotate dehydrogenases and their inhibitors and uses.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1873204Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells membrane vesicles assessed inhibition of BCRP- mediated transport of 3[H]-E1S for 1 to 5 mins using [3H]-estrone sulfate as substrate by rapid filtration technique2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1457211Antimalarial activity against Plasmodium falciparum Dd2 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting 2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID558841Antimalarial activity against Plasmodium falciparum IMT 10500 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID660950Antimalarial activity against Plasmodium berghei NS infected in CD1 mouse assessed as decrease in parasitemia at 20 mg/kg, po administered using Na2CO3 as vehicle measured on day 42012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
AID1155472Antiplasmodial activity against Plasmodium falciparum SB1 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID1593255Antimalarial activity against atovaquone-resistant Plasmodium falciparum Tm90-C2B infected in human erythrocytes by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1604306Inhibition of Schistosoma mansoni DHODH2019European journal of medicinal chemistry, Dec-01, Volume: 183Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.
AID683714Antimalarial activity against liver stages of Plasmodium berghei assessed as inhibition of cytochrome bc1 complex2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Targeting the liver stage of malaria parasites: a yet unmet goal.
AID1629461Antimalarial activity against chloroquine/mefloquine-sensitive Plasmodium falciparum 3D7 infected-erythrocytes assessed as parasite growth inhibition after 48 to 54 hrs by SYBR green 1-based replication method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Parallel inhibition of amino acid efflux and growth of erythrocytic Plasmodium falciparum by mefloquine and non-piperidine analogs: Implication for the mechanism of antimalarial action.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID558835Antimalarial activity against Plasmodium falciparum IMT Guy assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID157838In vitro antimalarial activity against chloroquine-resistant Plasmodium falciparum K12000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Phenyl beta-methoxyacrylates: a new antimalarial pharmacophore.
AID1160943Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in Balb/c mouse assessed as inhibition of parasitemia at 50 mg/kg, po qd administered as single dose on day 3 to 5 of exposure measured on day 6 post exposure by in vivo thomson2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID558830Antimalarial activity against Plasmodium falciparum FCR3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1733042Antimalarial activity against ring stage artemisinin-sensitive Plasmodium falciparum F32-TEM assessed as time taken for recrudescence by measuring parasitemia at 7 uM after 48 hrs2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID1593253Antimalarial activity against multidrug-resistant Plasmodium falciparum Dd2 infected in human erythrocytes by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1201529Selectivity index, ratio of CC50 for human HepG2 cells expressing CD81 to IC50 for liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD812015European journal of medicinal chemistry, May-05, Volume: 95Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
AID341606Antimicrobial activity against Babesia divergens 1903B2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1626157Antimalarial activity against Plasmodium berghei infected in mouse assessed as inhibition of parasitemia at 50 mg/kg, po administered as single dose measured on day 3 post drug exposure relative to untreated control2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID285505Inhibition of Toxoplasma gondii RH replication in human foreskin fibroblasts incubated for 24 hrs with drug after 36 hrs postinfection by immunofluorescence microscopy2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor of alternative (type II) NADH dehydrogenases.
AID663121Antimalarial activity against atoquinone-resistant Plasmodium falciparum TM90C2B containing cytochrome-b Y268S mutant2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
AID704267Cytotoxicity against human BJ cells after 72 hrs by luminescence analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.
AID519610Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1743687Inhibition of Cytochrome b-c1 complex I304M/R306K double mutant in Rhodobacter capsulatus MT-RBC12020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1274389Antimalarial activity against sporozoite stage of Plasmodium berghei yoelii infected in human HepG2 cells2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?
AID1247014Selectivity index, ratio of EC50 for human HepG2A16 cells to EC50 for chloroquine-resistant Plasmodium falciparum Dd2 infected in human erythrocyte2015European journal of medicinal chemistry, Sep-18, Volume: 102Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.
AID1457215Antimalarial activity against Plasmodium falciparum FCB infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting 2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1445971Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 ring stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based confocal microscopic method2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1629462Antimalarial activity against chloroquine/mefloquine-sensitive Plasmodium falciparum W2 assessed as parasite growth inhibition by [3H]hypoxanthine incorporation assay2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Parallel inhibition of amino acid efflux and growth of erythrocytic Plasmodium falciparum by mefloquine and non-piperidine analogs: Implication for the mechanism of antimalarial action.
AID1593288Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I/A138T double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID660949Antimalarial activity against Plasmodium berghei NS infected in CD1 mouse assessed as decrease in parasitemia at 20 mg/kg, po administered using DET as vehicle measured on day 42012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
AID704266Cytotoxicity against human HepG2 cells after 72 hrs by luminescence analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.
AID420343Antimalarial activity after 48 hrs against chloroquine-resistant Plasmodium falciparum W2 by [3H]hypoxanthine uptake2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Design, synthesis and structure-activity relationships of (1H-pyridin-4-ylidene)amines as potential antimalarials.
AID104327Effective dose was determined in vivo for 50% parasite (Plasmodium berghei) reduction in the male albino mice after oral administration2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Phenyl beta-methoxyacrylates: a new antimalarial pharmacophore.
AID729496Competitive inhibition of human purified recombinant DHODH in presence of cofactor ubiquinone2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
On dihydroorotate dehydrogenases and their inhibitors and uses.
AID1403756Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Antimalarial naphthoquinones. Synthesis via click chemistry, in vitro activity, docking to PfDHODH and SAR of lapachol-based compounds.
AID1810600Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay
AID1833128Induction of morphological changes in Toxoplasma gondii ESG reporter strain at 10 uM2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID279385Growth inhibition of Plasmodium falciparum as reduced [3H]hypoxanthine incorporation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID1593291Antimalarial activity against drug-resistant Plasmodium falciparum 3D7 harboring A82T/V259L double mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1625270Inhibition of Plasmodium falciparum NDH2 expressed in HEK293 cells by spectrophotometric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID248947Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.29 uM)2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
AID704269Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 expressing yeast DHODH infected in O-positive erythrocytes assessed as reduction in parasitemia after 72 hrs by spectrofluorometry in presence of PG2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.
AID495507Antimicrobial activity against Toxoplasma gondii type 2 ME49 strain orally infected in ip dosed IRF-8 deficient mouse brain assessed as decrease in Toxoplasma DNA level measured per 250 ng total DNA administered for 5 days after 3 days post 28 day 400 mg/2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii.
AID1733041Antimalarial activity against ring stage artemisinin-sensitive Plasmodium falciparum F32-TEM assessed as time taken for recrudescence by measuring parasitemia at 1 uM after 48 hrs2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID420344Antimalarial activity after 48 hrs against atovaquone-resistant Plasmodium falciparum FCR3 by [3H]hypoxanthine uptake2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Design, synthesis and structure-activity relationships of (1H-pyridin-4-ylidene)amines as potential antimalarials.
AID519612Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID495505Antimicrobial activity against GFP-expressing Toxoplasma gondii type 1 RH strain ip infected in NMRI mouse assessed as decrease in parasite DNA level in liver at 32 mg/kg, ip administered 3 days postinfection for 5 days by quantitative PCR analysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii.
AID104328Effective dose was determined in vivo for 50% parasite (Plasmodium berghei) reduction in the male albino mice after subcutaneous administration2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Phenyl beta-methoxyacrylates: a new antimalarial pharmacophore.
AID519622Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID576511Antiplasmodial activity against Plasmodium falciparum 3D7 by SYBR Green 1-based fluorescence assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1560628Antiplasmodial activity against luciferase expressing Plasmodium berghei sporozoites infected in human HuH7 cells assessed as reduction in parasite load preincubated for 1 hr followed by parasite infection and measured after 46 hrs by bioluminescence assa2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Molecular Design and Synthesis of Ivermectin Hybrids Targeting Hepatic and Erythrocytic Stages of
AID1240747Antimalarial activity against Plasmodium falciparum 3D7 infected in erythrocytes incubated for 48 hrs by [3H]hypoxanthine incorporation assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials.
AID1858874Antimalarial activity against Plasmodium falciparum W22021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID1894268Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in
AID1733046Antimalarial activity against ring stage artemisinin-resistant Plasmodium falciparum F32-ART5 assessed as time taken for recrudescence by measuring parasitemia pretreated with dihydroartemisinin for 6 hrs followed by treated at 7 uM for 48 hrs by Quiescen2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID422235Cytotoxicity against human KB cells assessed as [3H]hypoxanthine incorporation after 48 hrs2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Diterpene formamides from the tropical marine sponge Cymbastela hooperi and their antimalarial activity in vitro.
AID1676943Antiplasmodial activity against late trophozoite synchronized chloroquine-resistant Plasmodium falciparum Dd2 reduction in microbial growth at 6.6 nM measured after 12 hrs by Giemsa staining-based microscopic analysis2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Synthesis, Structure-Activity Relationship, and Antimalarial Efficacy of 6-Chloro-2-arylvinylquinolines.
AID1894267Antiplasmodial activity against asexual blood stage Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green dye based fluorescence assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1604305Inhibition of Babesia bovis DHODH2019European journal of medicinal chemistry, Dec-01, Volume: 183Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.
AID641578Antimalarial activity against chloroquine-, mefloquine-, pyrimethamine-,atovaquone-resistant ring stage Plasmodium falciparum TM90-C2B infected in human A positive erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones.
AID1125281Antimicrobial activity against blood-stage Plasmodium falciparum NF54 assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs by liquid scintillation counting2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP).
AID519615Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID558847Antimalarial activity against Plasmodium falciparum IMT Vol assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID519613Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID558832Antimalarial activity against Plasmodium falciparum HB3 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1240748Antimalarial activity against Plasmodium falciparum 3D7 infected in erythrocytes incubated for 72 hrs by [3H]hypoxanthine incorporation assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials.
AID1489623Antimalarial activity against blood stage form of GFP transfected Plasmodium berghei infected in mouse assessed as protection against parasitemia at 10 mg/kg, po administered on day 3, 4, 5 post infection measured on day 30 by Thompson test2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.
AID1391371Antiparasitic activity against tachyzoite stage of Toxoplasma gondii expressing beta-gal infected in HFF after 4 days by chlorophenol red-beta-D-galactosidase based assay2018Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9
One-pot, multicomponent synthesis of 2,3-disubstituted quinazolin-ones with potent and selective activity against Toxoplasma gondii.
AID1457205Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID370979Inhibition of Plasmodium falciparum DHOD2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.
AID1593296Inhibition of Plasmodium falciparum cytochrome b-c12019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1337668Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for chloroquine/pyrimethamine/proguanil-resistant Plasmodium falciparum K1 infected in human erythrocytes2017European journal of medicinal chemistry, Jan-05, Volume: 125Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold.
AID1416035Inhibition of recombinant Mycobacterium tuberculosis Rv1284 expressed in Escherichia coli BL21-Al cells assessed as enzyme residual activity at 25 uM measured for 10 secs by m-cresol purple staining based stopped-flow CO2 hydration assay relative to contr2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID1457210Antimalarial activity against Plasmodium falciparum TM90C2B infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation count2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1810596Antiplasmodial activity against asexual stage of chloroquine-sensitive Plasmodium falciparum D6 infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by SYBR green 1 staining based assay
AID1770442Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by SYBR green I fluorescence based assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Antiplasmodial 2-thiophenoxy-3-trichloromethyl quinoxalines target the apicoplast of Plasmodium falciparum.
AID1626152Cytotoxicity against mouse J774 cells2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1201526Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
AID1625268Inhibition of Plasmodium falciparum cytochrome bc1 expressed in HEK293 cells by spectrophotometric analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1625269Antimalarial activity against Plasmodium falciparum 3D72016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID1894270Antiplasmodial activity against Plasmodium falciparum NF54 expressing transgenic luciferase assessed as parasite kill rate at trophozoite stage incubated for 6 hrs by bioluminescence relative rate of kill (BRRoK) assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in
AID1592258Inhibition of human DHODH using DHO as substrate measured at 4 secs interval for 60 secs by DCIP reduction based indirect assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Ligand-based design, synthesis and biochemical evaluation of potent and selective inhibitors of Schistosoma mansoni dihydroorotate dehydrogenase.
AID384957Antimalarial activity against Plasmodium falciparum T9-96 infected Rhesus positive human erythrocytes by [3H]hypoxanthine uptake2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.
AID683702Antimalarial activity against liver stages of Plasmodium falciparum NF54 infected in human HepG2-A16 cells expressing CD81 assessed as growth inhibition of hepatic parasite after 5 days by fluorescence microscopy2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Targeting the liver stage of malaria parasites: a yet unmet goal.
AID558839Antimalarial activity against Plasmodium falciparum IMT 9881 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1733045Antimalarial activity against Plasmodium falciparum assessed as difference of time taken for recrudescence Plasmodium falciparum F32 ART1 between ring stage artemisinin-sensitive Plasmodium falciparum F32-TEM measured at 1 uM after 48 hrs2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID1125282Antimicrobial activity against blood-stage Plasmodium falciparum K1 assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs by liquid scintillation counting2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP).
AID370978Inhibition of Plasmodium falciparum NDH22009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.
AID1688326Antimalarial activity against Plasmodium falciparum 3D7 asexual forms incubated for 72 hrs by luminescence method2020European journal of medicinal chemistry, Feb-15, Volume: 188Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
AID384961Antimalarial activity against Plasmodium falciparum FCR3-A infected erythrocytes as [3H]hypoxanthine incorporation2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.
AID1391370Cytotoxicity against HFF by CellTiter96 AQueous one solution cell proliferation assay2018Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9
One-pot, multicomponent synthesis of 2,3-disubstituted quinazolin-ones with potent and selective activity against Toxoplasma gondii.
AID1626149Antimalarial activity against Plasmodium falciparum W22016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.
AID1140153Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 MRA-285 infected in human red blood cells assessed as suppression of parasitemia after 72 hrs by SYBR Green I-based fluorescence method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID1833149Anti-bradyzoite activity against Toxoplasma gondii ESG reporter stain infected in NHDF cells assessed as viable cells recovery causing host cell lysis at 1 uM measured after 15 days by optical microscopic analysis2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID1355303Plasmodicidal activity against Plasmodium falciparum 3D7A infected in erythrocytes assessed as parasite survival at 10 times IC50 pre-incubated for 24 hrs followed by compound washout and measured after 24 hrs by 1H-hypoxanthine incorporation assay (Rvb =2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Discovery of Marinoquinolines as Potent and Fast-Acting Plasmodium falciparum Inhibitors with in Vivo Activity.
AID1649410Antimalarial activity against multidrug resistant Plasmodium falciparum D6 infected in human erythrocytes measured after after 72 hrs by SYBR green dye based fluorescence assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID558837Antimalarial activity against Plasmodium falciparum IMT 31 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID517480Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum W2 infected in human A+ erythrocytes after 72 hrs by SYBR Green I assay2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID1489621Antimalarial activity against blood stage form of GFP transfected Plasmodium berghei infected in mouse assessed as inhibition of parasitemia at 10 mg/kg, po administered on day 3, 4, 5 post infection measured on day 6 by Thompson test relative to control2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.
AID1182743Antiplasmodial activity against Plasmodium falciparum K1 by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID1649412Antimalarial activity against multidrug resistant Plasmodium falciparum 7G8 infected in human erythrocytes measured after after 72 hrs by SYBR green dye based fluorescence assay2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
AID1457216Antimalarial activity against intraerythrocytic stage of Plasmodium falciparum assessed as time required for maximal killing effect at 10 times IC50 preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation coun2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1421908Cytotoxicity against human HepG2A16 cells expressing GFP-fused CD81 after 48 hrs by bioluminescence assay2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1155336Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs2014European journal of medicinal chemistry, Jul-23, Volume: 82Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
AID527264Antimalarial activity against liver stages of Plasmodium yoelii expressing GFP infected in human HepG2:CD81 cells after 43 hrs by immunofluorescence analysis2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1810601Therapeutic index, ratio of IC50 for cytotoxicity against human HepG2 cells to IC50 for antiplasmodial activity against asexual blood stage of multidrug-resistant Plasmodium falciparum D6 infected in human erythrocytes
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID384958Antimalarial activity as reduced parasitaemia against Plasmodium yoelii YM in CD1 mice (Mus musculus) after 7 peroral doses over 4 days2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID279384Growth inhibition of Plasmodium falciparum ring stage in infected erythrocytes by DAPI growth assay2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
AID1592259Selectivity Index, ratio of IC50 for human DHODH to IC50 for Schistosoma mansoni DHODH2019European journal of medicinal chemistry, Apr-01, Volume: 167Ligand-based design, synthesis and biochemical evaluation of potent and selective inhibitors of Schistosoma mansoni dihydroorotate dehydrogenase.
AID422234Antiplasmodial activity after 48 hrs against Plasmodium falciparum D6 by [3H]hypoxanthine uptake2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Diterpene formamides from the tropical marine sponge Cymbastela hooperi and their antimalarial activity in vitro.
AID1593258Antimalarial activity against luciferase-expressing Plasmodium berghei ANKA 676m1cl1 sporozoites infected in human HepG2A16 cells measured after 45 hrs by luciferase-luciferin based reporter assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID1201513Antiplasmodial activity against multi-drug resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as parasite growth inhibition after 72 hrs by SYBR Green I dye-based fluorescence assay2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
AID1436319Antimalarial activity against intraerythrocytic stage of Plasmodium falciparum 3D7A assessed as log (viable parasites +1) at 10 times IC50 after 48 hrs by [3H]-hypoxanthine incorporation assay (Rvb = 5 No_unit)2017European journal of medicinal chemistry, Jan-27, Volume: 126Novel inhibitors of Plasmodium falciparum based on 2,5-disubstituted furans.
AID558842Antimalarial activity against Plasmodium falciparum IMT 16332 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID601638Antimalarial activity against Plasmodium falciparum 3D7 infected in human A positive erythrocytes by [3H]hypoxanthine uptake assay in presence of serum in medium2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
AID558840Antimalarial activity against Plasmodium falciparum IMT 10336 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID558833Antimalarial activity against Plasmodium falciparum 106/1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID341607Antimicrobial activity against Babesia divergens 42012007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1445972Gametocytocidal activity against transgenic GFP-fused Plasmodium falciparum NF54 early stage gametocytes after 72 hrs by Mitotracker Red CMH2XRos staining based confocal microscopic method2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1247011Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in human erythrocyte assessed as growth inhibition by SYBR Green-1 assay2015European journal of medicinal chemistry, Sep-18, Volume: 102Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.
AID1190841Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 by SYBR Green-based method2015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
Synthesis and biological evaluation of adamantane-based aminophenols as a novel class of antiplasmodial agents.
AID1182792Antiplasmodial activity against Plasmodium falciparum Dd2 harboring mutations conferring drug-resistance by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1593290Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID780203Antiplasmodial activity against Plasmodium falciparum K1 infected in human erythrocytes after 72 hrs by SYBR Green I fluorescence assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.
AID510929Antimalarial activity against NITD609-resistant Plasmodium falciparum Dd2 Clone3 bearing P-type ATPase4 D1247Y mutations after 72 hrs by SYBR green based fluorescence assay2010Science (New York, N.Y.), Sep-03, Volume: 329, Issue:5996
Spiroindolones, a potent compound class for the treatment of malaria.
AID704270Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 expressing yeast DHODH infected in O-positive erythrocytes assessed as reduction in parasitemia after 72 hrs by spectrofluorometry2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.
AID1429842Antimalarial activity against GFP-fused Plasmodium berghei ANKA liver stage infected in HuH7 cells pretreated for 1 hr followed by parasite infection after 48 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.
AID1182791Antiplasmodial activity against Plasmodium falciparum SB1-A6 harboring mutations conferring drug-resistance by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1247013Cytotoxicity against human HepG2A16 cells after 48 hrs by MTT assay2015European journal of medicinal chemistry, Sep-18, Volume: 102Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.
AID1858883Cytotoxicity against HEK293 cells incubated for 48 hrs by MTT assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID663111Antimalarial activity against Plasmodium berghei infected in CD1 mouse assessed as decrease in parasitemia at 20 mg/kg, po administered using 5% DMSO and 5% EtOH in tetraglycol vehicle measured on day 4 relative to control2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).
AID1810292Antimalarial activity against chloroquine, pyrimethamine, mefloquine and atovaquone- resistant Plasmodium falciparum TM90-C2B infected in human erythrocytes assessed as reduction in parasite growth incubated for 48 hrs followed by addition of [3H]-hypoxan2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1
AID1593252Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in human erythrocytes by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID519614Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID725352Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBC by flow cytometry analysis2013European journal of medicinal chemistry, Jan, Volume: 59Addition of thiols to o-quinone methide: new 2-hydroxy-3-phenylsulfanylmethyl[1,4]naphthoquinones and their activity against the human malaria parasite Plasmodium falciparum (3D7).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID519616Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1125283Antimicrobial activity against blood-stage Plasmodium falciparum Dd2 assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs by liquid scintillation counting2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP).
AID1489612Antimalarial activity against pyrimethamine/chloroquine-resistant Plasmodium falciparum W2 infected in human type A-positive erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.
AID558844Antimalarial activity against Plasmodium falciparum IMT K2 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1416036Inhibition of recombinant Mycobacterium tuberculosis N-terminal Hi-tagged Rv3588c expressed in Escherichia coli BL21-Al cells assessed as enzyme residual activity at 25 uM measured for 10 secs by m-cresol purple staining based stopped-flow CO2 hydration a2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID1593289Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring M133I mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID558831Antimalarial activity against Plasmodium falciparum PA assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1626158Antimalarial activity against Plasmodium berghei infected in mouse assessed as inhibition of parasitemia at 50 mg/kg, po administered as single dose measured on day 6 post drug exposure relative to untreated control2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.
AID576507Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID1533160Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 measured after 48 hrs by SYBR green1 dye based fluorescence assay2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
Potent Antimalarial 2-Pyrazolyl Quinolone
AID729493Inhibition of rat purified recombinant DHODH2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
On dihydroorotate dehydrogenases and their inhibitors and uses.
AID519619Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID748224Inhibition of heme crystallization to hemozoin2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.
AID1125285Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP).
AID519611Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1445973Gametocytocidal activity against GFP-fused Plasmodium berghei liver stage gametocytes infected in human HepG2-A16-CD81-EGFP cells after 48 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1457075Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by s2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1593287Antimalarial activity against drug-resistant Plasmodium falciparum Dd2 harboring V259L mutant infected in human erythrocytes after 72 hrs by SYBR green 1-based fluorescence assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID558838Antimalarial activity against Plasmodium falciparum IMT 8425 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1894269Antiplasmodial activity against Plasmodium falciparum NF54 expressing transgenic luciferase assessed as parasite kill rate at trophozoite stage incubated for 72 hrs by bioluminescence relative rate of kill (BRRoK) assay2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in
AID683713Antimalarial activity against liver stages of Plasmodium berghei in human HepG2 cells assessed as inhibition of exoerythrocytic development at 1.85 nM administered 3 hrs after sporozite invasion measured after 48 hrs2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Targeting the liver stage of malaria parasites: a yet unmet goal.
AID517481Cytotoxicity against mouse J774 cells2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID1593257Selectivity index, ratio of IC50 for human HepG2 cells to IC50 for chloroquine-sensitive Plasmodium falciparum D6 infected in human erythrocytes2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
AID606570Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum W2 infected in human A positive erythrocytes after 72 hrs by SYBR Green I assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.
AID1858873Antimalarial activity against Plasmodium falciparum D62021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID1201510Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, May-05, Volume: 95Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID729494Inhibition of human purified recombinant DHODH2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
On dihydroorotate dehydrogenases and their inhibitors and uses.
AID1489613Antimalarial activity against mefloquine/chloroquine/atovaquone/pyrimethamine-resistant Plasmodium falciparum TM90-C2B infected in human type A-positive erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay2018Journal of medicinal chemistry, 02-22, Volume: 61, Issue:4
Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1182742Antiplasmodial activity against Plasmodium falciparum NF54 by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID1733035Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID558846Antimalarial activity against Plasmodium falciparum IMT L1 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1733037Antimalarial activity against ring stage artemisinin-resistant Plasmodium falciparum F32-ART5 assessed as time taken for recrudescence by measuring parasitemia at 1 uM after 48 hrs2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID519620Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-TOU infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID576510Antiplasmodial activity against multidrug-resistant Plasmodium falciparum TM90C2B by SYBR Green 1-based fluorescence assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID1810598Antiplasmodial activity against asexual blood stage of multidrug-resistant Plasmodium falciparum 7G8 infected in human erythrocytes assessed as reduction in parasite growth incubated for 72 hrs by SYBR green 1 staining based assay
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1833125Induction of stage conversion in Toxoplasma gondii ESG reporter strain at 1 uM2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID1626150Antimalarial activity against Plasmodium falciparum TM90-C2B2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.
AID517478Antimalarial activity against chloroquine, mefloquine, pyrimethamine and atovaquone-resistant Plasmodium falciparum TM90-C2B infected in human A+ erythrocytes after 72 hrs by SYBR Green I assay2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID1629463Antimalarial activity against trophozoite stage of Plasmodium falciparum 3D7 infected-erythrocytes assessed as reduction in Leu efflux after 4 hrs by UPLC method2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Parallel inhibition of amino acid efflux and growth of erythrocytic Plasmodium falciparum by mefloquine and non-piperidine analogs: Implication for the mechanism of antimalarial action.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1421921Selectivity index, ratio of IC50 for human HepG2A16 cells to IC50 for exo-erythrocytic stage of GFP-Luc-fused Plasmodium berghei ANKA infected in human HepG2 cells2018European journal of medicinal chemistry, Oct-05, Volume: 158One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
AID1247012Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocyte assessed as growth inhibition by SYBR Green-1 assay2015European journal of medicinal chemistry, Sep-18, Volume: 102Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.
AID341599Antiplasmodial activity against Plasmodium falciparum K12007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1587115Antiplasmodial activity against exoerythrocytic-stage of Plasmodium berghei ANKA infected in human HepG2 cells expressing CD81 pretreated with cells for 18 hrs followed by parasite infection and measured after 48 hrs by brightglo-luminescence assay2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Synthesis, Profiling, and in Vivo Evaluation of Cyclopeptides Containing
AID1153182Antiplasmodial activity against liver stage Plasmodium berghei infected in human HuH7 cells assessed as decrease in parasite load at 2 uM treated for 1 hr prior to infection measured after 48 hrs by Alamar blue assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Tetraoxane-pyrimidine nitrile hybrids as dual stage antimalarials.
AID1192799Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by SYBR green-based assay2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Synthesis and in vitro evaluation of novel 8-aminoquinoline-pyrazolopyrimidine hybrids as potent antimalarial agents.
AID1457206Antimalarial activity against Plasmodium falciparum K1 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation counting m2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1625271Antimalarial activity against atovaquone-resistant Plasmodium falciparum TM90C2B2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.
AID1592257Inhibition of Schistosoma mansoni DHODH using DHO as substrate measured at 4 secs interval for 60 secs by DCIP reduction based indirect assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Ligand-based design, synthesis and biochemical evaluation of potent and selective inhibitors of Schistosoma mansoni dihydroorotate dehydrogenase.
AID748223Cytotoxicity against human HepG2 cells after 48 hrs by Alamar Blue assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.
AID519621Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
AID1160955Antimalarial activity against Plasmodium berghei ANKA expressing GFP infected in Balb/c mouse assessed as mouse cured from disease at 50 mg/kg, po qd administered as single dose on day 3 to 5 of exposure measured on day 30 post exposure by in vivo thomson2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID29360Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID558826Antimalarial activity against Plasmodium falciparum 3D7 assessed as incorporation of [3H]hypoxanthine after 48 hrs by scintillation counter2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
AID1182790Antiplasmodial activity against Plasmodium falciparum W2 harboring mutations conferring drug-resistance by SYBR-green based assay2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
AID370980Inhibition of Saccharomyces cerevisiae DHOD2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.
AID1657900Inhibition of recombinant human DHODH expressed in baculovirus infected insect cells using dihydroorotate as substrate and decylubiquinone as co-substrate by 2,6-dichlorophenol-indophenol-coupled spectrophotometric analysis2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Bifunctional Naphtho[2,3-
AID1733048Antimalarial activity against Plasmodium falciparum assessed as difference of time taken for recrudescence Plasmodium falciparum F32 ART1 between ring stage artemisinin-sensitive Plasmodium falciparum F32-TEM measured at 7 uM after 48 hrs2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID704272Antimalarial activity against chloroquine/pyrimethamine-resistant Plasmodium falciparum K1 infected in O-positive erythrocytes assessed as reduction in parasitemia after 72 hrs by spectrofluorometry2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.
AID1457207Antimalarial activity against Plasmodium falciparum T9/94 infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation preincubated for 24 hrs followed by [3H]-hypoxanthine addition measured after 24 hrs by scintillation countin2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID1727376Parasiticidal activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in erythrocytes assessed as reduction in parasitemia at 6.6 nM incubated for 6 to 12 hrs followed by compound washout and then incubated for 96 hrs by Giemsa staining 2021European journal of medicinal chemistry, Jan-01, Volume: 209Discovery of fast-acting dual-stage antimalarial agents by profiling pyridylvinylquinoline chemical space via copper catalyzed azide-alkyne cycloadditions.
AID1155470Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR I method2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
AID285479Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes (stage 2 & 3)2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID607828Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs using Hema 3 staining by microscopic analysis2011Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15
Synthesis and biological activities of 4-N-(anilinyl-n-[oxazolyl])-7-chloroquinolines (n=3' or 4') against Plasmodium falciparum in in vitro models.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID104330Effective dose was determined in vivo for 90% parasite (Plasmodium berghei) reduction in the male albino mice after oral administration2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Phenyl beta-methoxyacrylates: a new antimalarial pharmacophore.
AID341600Antiplasmodial activity against Plasmodium falciparum NF542007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID341601Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB9002007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160).
AID1733036Selective index, ratio of CC50 for African green monkey Vero cells to IC50 for plasmodium falciparum2021Bioorganic & medicinal chemistry letters, 05-01, Volume: 39Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites.
AID1858875Antimalarial activity against Plasmodium falciparum TM91C2352021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID285480Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes (stage 4 & 5)2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1833134Anti-bradyzoite activity against Toxoplasma gondii ESG reporter strain infected in NHDF cells assessed as cell lysis measured after 21 days2021Bioorganic & medicinal chemistry, 11-15, Volume: 50In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1801889Cytochrome b Enzyme Assay from Article 10.1016/j.chembiol.2016.06.016: \\A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance.\\2016Cell chemical biology, 08-18, Volume: 23, Issue:8
A Fungal-Selective Cytochrome bc
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (926)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.22)18.7374
1990's185 (19.98)18.2507
2000's283 (30.56)29.6817
2010's327 (35.31)24.3611
2020's129 (13.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 92.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index92.98 (24.57)
Research Supply Index7.00 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index166.64 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (92.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials100 (10.03%)5.53%
Reviews114 (11.43%)6.00%
Case Studies136 (13.64%)4.05%
Observational6 (0.60%)0.25%
Other641 (64.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (43)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effectiveness and Safety Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria : a Multicentric Study [NCT01150344]Phase 4317 participants (Actual)Interventional2010-07-31Completed
Multicenter Therapeutic Efficacy Assessment of Pyronaridine-Artesunate (Pyramax®) and New Drug Combinations With Atovaquone-Proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Cambodia [NCT03726593]Phase 4252 participants (Anticipated)Interventional2018-10-04Recruiting
Evaluation of the Prophylactic Antimalarial Activity of a Single Dose of DSM265 in Non-immune Healthy Adult Volunteers by Controlled Human Malaria Infection With PfSPZ Challenge [NCT02450578]Phase 122 participants (Actual)Interventional2015-10-31Completed
Identification of Pre-erythrocytic Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis [NCT02080026]15 participants (Actual)Interventional2014-06-30Completed
Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection [NCT02098590]40 participants (Actual)Interventional2014-10-31Completed
Safety and Protective Efficacy of Chemoprophylaxis and Sporozoite Immunization With Plasmodium Falciparum NF135 Against Homologous and Heterologous Challenge Infection in Healthy Volunteers in the Netherlands [NCT03813108]43 participants (Actual)Interventional2019-04-01Terminated(stopped due to Subject withdrawals after temporal suspension of the trial (for personal, logistic reasons). At time of reinitiation the number of enrolled subjects did not meet the predefined threshold for continuation of the trial.)
'Controlled Human Malaria Infection Study to Assess Gametocytaemia and Mosquito Transmissibility in Participants Challenged With Plasmodium Falciparum by Sporozoite Challenge to Establish a Model for the Evaluation of Transmission-blocking Interventions' [NCT02836002]Phase 1/Phase 229 participants (Actual)Interventional2016-06-30Completed
An Open-label, Randomized, Single-center, Parallel Group Study of the Effects of Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium F [NCT00444106]Phase 4265 participants (Actual)Interventional2007-05-31Completed
Pre-operative Window of Opportunity Study of the Effects of Atovaquone on Hypoxia in Non-small Cell Lung Carcinoma [NCT02628080]Early Phase 146 participants (Actual)Interventional2016-05-31Completed
Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Atovaquone/Proguanil Chemoprophylaxis [NCT02858817]Phase 130 participants (Actual)Interventional2016-11-28Completed
A Phase 1 Clinical Trial To Evaluate The Safety and Infectivity Of Direct Venus Inoculation of Aseptic, Purified, Cryopreserved Plasmodium Falciparum 7G8 And NF54 Challenge Strains (PfSPZ) in a Head-To-Head Comparative Study [NCT04203186]0 participants (Actual)Interventional2020-03-31Withdrawn(stopped due to Funding was lost due to the COVID19 Pandemic)
A Randomized, Open-Label Trial of High Dose Atovaquone Versus Low Dose Atovaquone Versus Aerosolized Pentamidine for Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With HIV Infection Who Are Intolerant of TMP/SMX [NCT00002340]Phase 3615 participants InterventionalCompleted
A Randomized, Open-label, Three-period Crossover Clinical Trial to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers [NCT04568772]Phase 119 participants (Actual)Interventional2020-11-25Completed
A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination With Radical Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer [NCT04648033]Phase 121 participants (Actual)Interventional2020-12-07Completed
Oral Corticosteroids Therapy and Interstitial Fibrosis in Patients With Pneumocystis Jirovecii Pneumonia (PCP) and pO2 of >70 at Presentation. [NCT00636935]Phase 40 participants (Actual)Interventional2008-02-29Withdrawn(stopped due to No patient completed protocol)
Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension. - A Single Oral Dose Study to Investigate Pharmacokinetics of Atovaquone and Proguanil From Combination Tablets and Atovaquone From Atovaquone Susp [NCT01858831]Phase 130 participants (Actual)Interventional2012-04-30Completed
Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer [NCT05998135]Phase 228 participants (Anticipated)Interventional2023-09-01Not yet recruiting
A Phase Ii/Iii, Randomized, Double Blind, Comparative Trial Of Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America [NCT00084227]Phase 2/Phase 3244 participants (Actual)Interventional2004-07-31Completed
Phase 2a Proof-of-Concept, Multicenter, Randomized, Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of the Combination M5717-pyronaridine as Chemoprevention in Asymptomatic Adults and Adolescents With Plasmodium Fa [NCT05974267]Phase 2192 participants (Anticipated)Interventional2023-11-28Recruiting
A Randomized, Double-Blind Study of 566C80 Versus Septra (Trimethoprim/Sulfamethoxazole) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients [NCT00000655]Phase 2300 participants InterventionalCompleted
A Phase 2a Open Label Study of the Safety and Efficacy of a Single Dose of Weekly Chloroquine (CQ) and Azithromycin (AZ) Administered in Combination for Malaria Prophylaxis in Healthy Adults Challenged With 7G8 Chloroquine-Resistant Plasmodium Falciparum [NCT03278808]Phase 20 participants (Actual)Interventional2018-09-17Withdrawn(stopped due to The IND has been withdrawn from FDA)
Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-exposure Prophylaxis. A Randomized, Open Label, Trial in Healthy US Adults Age 18-60 Years [NCT02564471]Phase 4103 participants (Actual)Interventional2016-11-11Completed
Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis [NCT00000794]Phase 2100 participants InterventionalCompleted
A Trial of Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults (ATACC AML) [NCT03568994]Early Phase 126 participants (Actual)Interventional2018-07-10Active, not recruiting
A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole [NCT00001996]Phase 20 participants InterventionalCompleted
The Influence of Atazanavir-ritonavir and Efavirenz on Atovaquone Pharmacokinetics in HIV-infected Volunteers [NCT01479361]Phase 136 participants (Actual)Interventional2011-10-31Completed
[NCT00451139]Phase 40 participants InterventionalCompleted
Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection [NCT04339426]Phase 23 participants (Actual)Interventional2020-04-20Terminated(stopped due to Closed due to poor enrollment)
A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria [NCT01442168]Phase 1/Phase 253 participants (Actual)Interventional2011-09-30Terminated
Controlled Human Malaria Infection Study to Assess Gametocytemia and Mosquito Transmissibility in Participants Challenged With Plasmodium Falciparum by Sporozoite or Blood Stage Challenge to Establish a Model for the Evaluation of Transmission-blocking In [NCT03454048]24 participants (Actual)Interventional2018-05-07Completed
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides [NCT00000802]Phase 3700 participants InterventionalCompleted
Atovaquone for Treatment of COVID-19 [NCT04456153]Phase 260 participants (Actual)Interventional2020-07-22Completed
An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine [NCT00001990]0 participants InterventionalCompleted
Drug Interactions Between ATOvaquone Used in MAlaria Prophylaxis and Antiretroviral Agents in HIV-1 Infected Patients (ATOMA) [NCT00421473]Phase 479 participants (Actual)Interventional2007-03-31Completed
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine [NCT00001994]0 participants InterventionalCompleted
A Randomized, Phase II/III, Double-Blind, Two-Armed Study of Micronized Atovaquone and Azithromycin (AT/AZ) as Compared to Trimethoprim-Sulfamethoxazole (TMP/SMX) in the Prevention of Serious Bacterial Infections When Used in Children Aged 3 Months to 19 [NCT00000811]Phase 2690 participants InterventionalCompleted
Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children [NCT00000773]Phase 124 participants InterventionalCompleted
A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia [NCT00001991]0 participants InterventionalCompleted
A Longitudinal Study of Chloroquine as Monotherapy or in Combination With Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria in Children in Blantyre, Malawi [NCT00379821]Phase 3640 participants (Actual)Interventional2007-02-28Completed
A Phase II, Open Label, Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of Intravenous Artesunate in Adults With Uncomplicated Malaria [NCT00298610]Phase 230 participants (Actual)Interventional2006-03-31Completed
Pilot Evaluation of Weekly Dosing of Atovaquone/Proguanil (Malarone ®) for Malaria Chemoprophylaxis [NCT00984256]Phase 235 participants (Actual)Interventional2009-09-30Completed
A Randomised, Open Label 2-period Crossover Study to Evaluate the Relative Bioavailability of Atoguanil Compared to Malarone® in Healthy Adult Participants in the Fed State [NCT04866602]Phase 116 participants (Actual)Interventional2021-11-17Completed
Therapeutic Efficacy of Atovaquone-proguanil and Artesunate-atovaquone-proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Areas of Multidrug Resistance in Cambodia. [NCT02297477]Phase 4205 participants (Actual)Interventional2014-12-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00298610 (7) [back to overview]Safety - Severity of Adverse Events
NCT00298610 (7) [back to overview]Safety - Serious Adverse Event (SAE) Relationship to Study Drug
NCT00298610 (7) [back to overview]Safety - Adverse Events Relationship to Study Drug
NCT00298610 (7) [back to overview]Percentage of Parasite Clearance
NCT00298610 (7) [back to overview]Number of Subjects With Fever Clearance
NCT00298610 (7) [back to overview]Change in Percentage of Parasites Detected at 48 Hours
NCT00298610 (7) [back to overview]Safety - Severity of Serious Adverse Events (SAE's)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Creatinine in Each Treatment Arm (Renal Function)
NCT00379821 (38) [back to overview]Mean Hemoglobin at the Last Study Visit in Each Treatment Arm for the Age Group of Participants 3 Years of Age or Younger.
NCT00379821 (38) [back to overview]Mean Hemoglobin at the Last Study Visit in Each Treatment Arm for the Age Group of Participants Greater Than 3 Years to 5 Years of Age.
NCT00379821 (38) [back to overview]Nearest Neighbor Index as a Measure of Spatial Pattern of the Distribution of Malaria Cases in Ndirande
NCT00379821 (38) [back to overview]Number of Cases of Severe Malaria in Each Treatment Arm
NCT00379821 (38) [back to overview]Number of Clinical Malaria Episodes Per Year of Follow-up
NCT00379821 (38) [back to overview]Number of Participants Infected With Parasites With the Mutation Pfcrt 76T at Recrudescent Episodes of Malaria
NCT00379821 (38) [back to overview]Number of Participants Infected With Parasites With the Mutation Pfcrt 76T on Day 0 of the Initial Episode of Malaria
NCT00379821 (38) [back to overview]Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm
NCT00379821 (38) [back to overview]Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm
NCT00379821 (38) [back to overview]Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm
NCT00379821 (38) [back to overview]Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm
NCT00379821 (38) [back to overview]Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm
NCT00379821 (38) [back to overview]Pharmacokinetics of Chloroquine Represented by Maximum Concentration (Cmax)
NCT00379821 (38) [back to overview]Number of Participants With New and Recrudescent Infections After Subsequent New Episodes
NCT00379821 (38) [back to overview]Number of Participants With New and Recrudescent Malaria Infections After Initial Treatment
NCT00379821 (38) [back to overview]Time to First Malaria Episode in Participants Who Travelled and Slept Outside the City Versus Those Who Did Not Travel and Sleep Outside the City.
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]"Number of Participants in Each Treatment Arm Who Change From Normal to Abnormal on Any Questions of the Neurological Examination"
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)
NCT00379821 (38) [back to overview]Pharmacokinetics of Chloroquine Represented by Time of Maximal Concentration (Tmax) and Chloroquine Half-life
NCT00444106 (4) [back to overview]Relationship Between Changes in Auditory Function and Treatment Groups
NCT00444106 (4) [back to overview]Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test)
NCT00444106 (4) [back to overview]Auditory Changes Following 3 Days of Treatment at Days 3, 7, 28, and 42 Days as Assessed by Pure Tone Thresholds Assessments (a Type of Hearing Test)
NCT00444106 (4) [back to overview]Efficacy of Polymerase Chain Reaction (PCR) Adjusted Malaria Cure Rates of the Three Treatment Regimens at Days 14, 28 and 42
NCT00984256 (3) [back to overview]Measured Concentrations of Plasma Atovaquone With Determinations of T1/2.
NCT00984256 (3) [back to overview]Measured Concentrations of Plasma Atovaquone With Determinations of Area Under the Curve
NCT00984256 (3) [back to overview]Prophylactic Efficacy of 3 Different Doses of Atovaquone/Proguanil (Malarone@) Given 1 Week Before Infectious Sporozoite Challenge Using the P. Falciparum Human Challenge Model.
NCT02450578 (13) [back to overview]Number of Participants With Adverse Events as a Measure of Safety & Tolerability of DSM265
NCT02450578 (13) [back to overview]Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Plasmodium Falciparum Sporozoite Challenge Inoculum
NCT02450578 (13) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety & Tolerability of Malarone
NCT02450578 (13) [back to overview]Pre-patent Period
NCT02450578 (13) [back to overview]DSM265 Pharmacokinetics Profile - AUC 0-∞, AUC 0-168h, and AUC 0-480h
NCT02450578 (13) [back to overview]DSM265 Pharmacokinetics Profile - C Max
NCT02450578 (13) [back to overview]DSM265 Pharmacokinetics Profile - CL/F
NCT02450578 (13) [back to overview]DSM265 Pharmacokinetics Profile - T 1/2
NCT02450578 (13) [back to overview]DSM265 Pharmacokinetics Profile - T Max
NCT02450578 (13) [back to overview]DSM265 Pharmacokinetics Profile - Vz/F
NCT02450578 (13) [back to overview]DSM450 Pharmacokinetics Profile - AUC 0-t, AUC 0-168h, and AUC 0-480h
NCT02450578 (13) [back to overview]DSM450 Pharmacokinetics Profile - T Max
NCT02450578 (13) [back to overview]DSM450 Pharmacokinetics Profile - Cmax
NCT02564471 (4) [back to overview]GMT Over Protective Titer Prior to Third Dose of PCECV
NCT02564471 (4) [back to overview]Geometric Mean Titer (GMT) 14 Days Post Fourth Dose Post Exposure Prophylaxis (PEP) With Purified Chick Embryo Cell Vaccine (PCECV) in Each Malaria Prophylaxis Group Compared to Control to Determine if a Fifth Dose of PEP Would Add Value
NCT02564471 (4) [back to overview]GMT Over Protective Titer 28 Days Post Fourth Dose of PCECV
NCT02564471 (4) [back to overview]GMT Over Protective Titer Prior Fourth Dose of PCECV
NCT03454048 (8) [back to overview]AUC Gametocytes
NCT03454048 (8) [back to overview]Frequency of Adverse Events in the CHMI-trans Model
NCT03454048 (8) [back to overview]Gametocyte Commitment
NCT03454048 (8) [back to overview]Gametocyte Prevalence
NCT03454048 (8) [back to overview]Gametocyte Sex-ratio
NCT03454048 (8) [back to overview]Number of Participants Infectious for Mosquitoes Through DFA
NCT03454048 (8) [back to overview]Peak Density Gametocytes
NCT03454048 (8) [back to overview]Magnitude of Adverse Events in the CHMI-trans Model
NCT03813108 (5) [back to overview]Frequency of Adverse Events After NF135.C10 CPS Immunization
NCT03813108 (5) [back to overview]Magnitude of Adverse Events After NF135.C10 CPS Immunization
NCT03813108 (5) [back to overview]Break Through Infections
NCT03813108 (5) [back to overview]Break Through Infections
NCT03813108 (5) [back to overview]Time to Parasitemia
NCT04456153 (7) [back to overview]Secondary Between Group Differences in Viral Load
NCT04456153 (7) [back to overview]Stratifed by Remdesivir
NCT04456153 (7) [back to overview]Primary Analysis
NCT04456153 (7) [back to overview]Percentage With 2 Log Viral Load Drop at Day 3
NCT04456153 (7) [back to overview]Change in Viral Load at Day 10 Stratified by Sex
NCT04456153 (7) [back to overview]Area Under the Curve Copies/ml*Day at Day 7
NCT04456153 (7) [back to overview]Number of Participants With Change in Ordinal Scale ≥2 Points by Day 15.

Safety - Severity of Adverse Events

Determine the safety (defined as severity of AE's using the Common Toxicity Criteria) (NCT00298610)
Timeframe: up to 14 days

InterventionNumber of adverse events (Number)
MildModerateSevere
Artesunate and Malarone123176

[back to top]

Safety - Serious Adverse Event (SAE) Relationship to Study Drug

Determine the safety (defined as relationship to study drug of SAE's) (NCT00298610)
Timeframe: Up to 14 days

InterventionNumber of events (Number)
None or RemotePossible, Probable, Definate
Artesunate and Malarone01

[back to top]

Safety - Adverse Events Relationship to Study Drug

Determine the safety (defined as relationship to study drug of AE's and SAE's) (NCT00298610)
Timeframe: up to 14 days

InterventionNumber of adverse events (Number)
None or remotePossible, probable, definate
Artesunate and Malarone8957

[back to top]

Percentage of Parasite Clearance

The target variable is detection (percentage) of asexual stage parasites of Plasmodium falciparum malaria in bloodstream by Giemsa - stained microscopy of thick and thin blood smears (NCT00298610)
Timeframe: 24 and 48 hours post dose

Interventionpercentage of parasite clearance (Mean)
24 hours post dose48 hours post dose
Artesunate and Malarone99.42199.998

[back to top]

Number of Subjects With Fever Clearance

Temperature is measured by oral digital thermometers, and fever clearance time is defined as the first time with resolution of fever (<37.5C) sustained for 24 hours (NCT00298610)
Timeframe: Within 48 hours post dose

InterventionParticipants (Count of Participants)
Artesunate and Malarone29

[back to top]

Change in Percentage of Parasites Detected at 48 Hours

Change in Percentage of Parasites Detected at 48 Hours. With positive numbers to represent increases and negative numbers to represent decreases (NCT00298610)
Timeframe: 48 hours

Interventionpercentage of parasite change (Mean)
Artesunate and Malarone99.998

[back to top]

Safety - Severity of Serious Adverse Events (SAE's)

Determine the safety (defined as severity of SAE's using the Common Toxicity Criteria) (NCT00298610)
Timeframe: up to 14 days

InterventionNumber of events (Number)
MildModerateSevere
Artesunate and Malarone001

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 0 of second subsequent malaria episode (Episode 2)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate26.1
Chloroquine Plus Atovaquone-Proguanil23.0
CQ Plus Azithromycin23.3
CQ Monotherapy23.5

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 0 of third subsequent malaria episode (Episode 3)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate26.4
Chloroquine Plus Atovaquone-Proguanil20.7
CQ Plus Azithromycin18.6
CQ Monotherapy16.2

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 14 of first subsequent malaria episode (Episode 1)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate14.5
Chloroquine Plus Atovaquone-Proguanil14.2
CQ Plus Azithromycin18.3
CQ Monotherapy17.2

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 14 of fourth subsequent malaria episode (Episode 4)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Atovaquone-Proguanil13.9

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 14 of initial malaria episode (Episode 0)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate14.3
Chloroquine Plus Atovaquone-Proguanil16.2
CQ Plus Azithromycin17.8
CQ Monotherapy15.5

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 14 of second subsequent malaria episode (Episode 2)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate116
Chloroquine Plus Atovaquone-Proguanil14.7
CQ Plus Azithromycin17.3
CQ Monotherapy16.3

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 14 of third subsequent malaria episode (Episode 3)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate17.8
Chloroquine Plus Atovaquone-Proguanil13.6
CQ Plus Azithromycin15.3
CQ Monotherapy14.3

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 0 of first subsequent malaria episode (Episode 1)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate43.9
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin43.7
CQ Monotherapy43.6

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 0 of fourth subsequent malaria episode (Episode 4)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 0 of initial malaria episode (Episode 0)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.3

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 0 of third subsequent malaria episode (Episode 3)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 0 of second subsequent malaria episode (Episode 2)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy46.4

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 14 of first subsequent malaria episode (Episode 1)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 14 of fourth subsequent malaria episode (Episode 4)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Atovaquone-Proguanil44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 14 of initial malaria episode (Episode 0)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 14 of second subsequent malaria episode (Episode 2)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.2

[back to top]

Mean Creatinine in Each Treatment Arm (Renal Function)

Creatine values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. Samples that were below the limit of detection were reported as 44.2 micromoles/liter, equivalent to the lower limit of detection. (NCT00379821)
Timeframe: Day 14 of third subsequent malaria episode (Episode 3)

InterventionMicromole/Liter (Mean)
Chloroquine Plus Artesunate44.2
Chloroquine Plus Atovaquone-Proguanil44.2
CQ Plus Azithromycin44.2
CQ Monotherapy44.2

[back to top]

Mean Hemoglobin at the Last Study Visit in Each Treatment Arm for the Age Group of Participants 3 Years of Age or Younger.

Hemoglobin values were assessed from blood collected at the last study visit at one year after enrollment. Group means are stratified by participants 3 years of age and under, and over 3 to 5 years of age. (NCT00379821)
Timeframe: 1 year

InterventionGrams/Deciliter (Mean)
Chloroquine Plus Artesunate11.6
Chloroquine Plus Atovaquone-Proguanil11.7
CQ Plus Azithromycin12.2
CQ Monotherapy11.8

[back to top]

Mean Hemoglobin at the Last Study Visit in Each Treatment Arm for the Age Group of Participants Greater Than 3 Years to 5 Years of Age.

Hemoglobin values were assessed from blood collected at the last study visit at one year after enrollment. Group means are stratified by participants 3 years of age and under, and over 3 to 5 years of age. (NCT00379821)
Timeframe: 1 year

InterventionGrams/Deciliter (Mean)
Chloroquine Plus Artesunate12.5
Chloroquine Plus Atovaquone-Proguanil12.3
CQ Plus Azithromycin12.1
CQ Monotherapy12.5

[back to top]

Nearest Neighbor Index as a Measure of Spatial Pattern of the Distribution of Malaria Cases in Ndirande

The Global Positioning System (GPS) was used to establish the coordinates of participants' homes. The distribution of these coordinates was analyzed for evidence of clustering, or occurring closer together than would be expected on the basis of chance. Nearest Neighbor Index is a ratio of the observed mean distance over the expected mean distance. If the index is less than 1, the pattern exhibits clustering. If the index is greater than 1, the trend is toward dispersion. (NCT00379821)
Timeframe: 1 year

InterventionIndex (Number)
All Groups0.328

[back to top]

Number of Cases of Severe Malaria in Each Treatment Arm

A case of severe malaria included one or more of the following: Hemoglobin ≤5 g/dL; prostration; respiratory distress; bleeding; recent seizures, coma or obtundation (Blantyre coma score < 5); inability to drink, or persistent vomiting. All cases were then adjudicated by a panel of investigators prior to analysis. (NCT00379821)
Timeframe: 1 Year

InterventionCases of severe malaria (Number)
Chloroquine Plus Artesunate0
Chloroquine Plus Atovaquone-Proguanil2
CQ Plus Azithromycin2
CQ Monotherapy6

[back to top]

Number of Clinical Malaria Episodes Per Year of Follow-up

Clinical malaria episode was defined as at least one symptom of malaria and a positive malaria smear. The number of clinical malaria episodes (not including the initial malaria episode) reported by participants during follow up is presented as the number per Person Years at Risk (PYAR). (NCT00379821)
Timeframe: 1 year

InterventionEpisodes per PYAR (Number)
Chloroquine Plus Artesunate0.61
Chloroquine Plus Atovaquone-Proguanil0.68
CQ Plus Azithromycin0.64
CQ Monotherapy0.59

[back to top]

Number of Participants Infected With Parasites With the Mutation Pfcrt 76T at Recrudescent Episodes of Malaria

Participants were enrolled in the study at the time of the initial episode of malaria. If the participant presented with a subsequent episode of malaria at any time during the one year of follow-up, the presence of parasites with the mutation pfCRT 76T was measured with filter paper specimens collected at the time of enrollment and with successful parasite DNA amplification using pyrosequencing. (NCT00379821)
Timeframe: Recrudescent episodes of malaria within one year of enrollment

Interventionparticipants (Number)
Chloroquine Plus Artesunate0
Chloroquine Plus Atovaquone-Proguanil0
CQ Plus Azithromycin1
CQ Monotherapy0

[back to top]

Number of Participants Infected With Parasites With the Mutation Pfcrt 76T on Day 0 of the Initial Episode of Malaria

The presence of parasites with the mutation pfCRT 76T was measured with filter paper specimens collected at the time of enrollment and with successful parasite DNA amplification using pyrosequencing. (NCT00379821)
Timeframe: Day 0 of initial episode of malaria

Interventionparticipants (Number)
Chloroquine Plus Artesunate1
Chloroquine Plus Atovaquone-Proguanil0
CQ Plus Azithromycin0
CQ Monotherapy0

[back to top]

Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm

Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure. (NCT00379821)
Timeframe: Day 28 of first subsequent malaria episode (Episode 1)

InterventionParticipants (Number)
Chloroquine Plus Artesunate46
Chloroquine Plus Atovaquone-Proguanil42
CQ Plus Azithromycin37
CQ Monotherapy39

[back to top]

Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm

Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure. (NCT00379821)
Timeframe: Day 28 of fourth subsequent malaria episode (Episode 4)

InterventionParticipants (Number)
Chloroquine Plus Atovaquone-Proguanil2
CQ Plus Azithromycin1

[back to top]

Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm

Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure. (NCT00379821)
Timeframe: Day 28 of initial malaria episode (Episode 0)

InterventionParticipants (Number)
Chloroquine Plus Artesunate143
Chloroquine Plus Atovaquone-Proguanil133
CQ Plus Azithromycin137
CQ Monotherapy135

[back to top]

Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm

Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure. (NCT00379821)
Timeframe: Day 28 of second subsequent malaria episode (Episode 2)

InterventionParticipants (Number)
Chloroquine Plus Artesunate17
Chloroquine Plus Atovaquone-Proguanil14
CQ Plus Azithromycin12
CQ Monotherapy6

[back to top]

Number of Participants With Day 28 Adequate Clinical and Parasitologic Response in Each Treatment Arm

Adequate clinical and parasitologic response (ACPR) was defined as the absence of parasitemia at Day 28 and without previously meeting any of the criteria of early treatment or late clinical failure. (NCT00379821)
Timeframe: Day 28 of third subsequent malaria episode (Episode 3)

InterventionParticipants (Number)
Chloroquine Plus Artesunate4
Chloroquine Plus Atovaquone-Proguanil4
CQ Plus Azithromycin6
CQ Monotherapy0

[back to top]

Pharmacokinetics of Chloroquine Represented by Maximum Concentration (Cmax)

1727 non-zero concentration measurements from 479 participants were pooled and used for population pharmacokinetic modeling in Monolix413s. Compartmental population pharmacokinetic modeling was used due to highly sparse data. The model was parameterized in terms of absorption rate constant for chloroquine (Ka), apparent clearance for chloroquine (CL/F, with F as the unknown oral bioavailability), apparent volume of distribution of the central and peripheral compartments for chloroquine (Vd/F), and the inter-compartmental clearance for chloroquine (Q/F). Only these primary population pharmacokinetic parameters could be estimated using the type of data collected. The best-fit population PK model was then used to estimate individual parameter estimates to derive Cmax in nanograms per milliliter (ng/mL). (NCT00379821)
Timeframe: Day 0 - Day 28

Interventionng/mL chloroquine (Median)
Chloroquine Plus Artesunate351.0
Chloroquine Plus Atovaquone-Proguanil345.1
CQ Plus Azithromycin353.1
CQ Monotherapy384.2

[back to top]

Number of Participants With New and Recrudescent Infections After Subsequent New Episodes

Participants were enrolled at the time of initial malaria episode and treated. Subsequent to treatment, participants who subsequently suffered new malaria episodes were monitored for the additional occurrence of new and recrudescent malaria infections, which were distinguished by analysis of the infecting parasites using merozoite surface protein-2 polymorphic gene length variation. (NCT00379821)
Timeframe: Day 28 to 1 year

,,,
Interventionparticipants (Number)
New infectionsRecrudescent infections
Chloroquine Plus Artesunate00
Chloroquine Plus Atovaquone-Proguanil00
CQ Monotherapy11
CQ Plus Azithromycin12

[back to top]

Number of Participants With New and Recrudescent Malaria Infections After Initial Treatment

Participants were enrolled at the time of initial malaria episode and treated. Subsequent to treatment, subjects were monitored for the occurrence of new and recrudescent malaria infections, which were distinguished by analysis of the infecting parasites using merozoite surface protein-2 polymorphic gene length variation. (NCT00379821)
Timeframe: 28 days to 1 year

,,,
Interventionparticipants (Number)
New infectionsRecrudescent infections
Chloroquine Plus Artesunate01
Chloroquine Plus Atovaquone-Proguanil00
CQ Monotherapy00
CQ Plus Azithromycin10

[back to top]

Time to First Malaria Episode in Participants Who Travelled and Slept Outside the City Versus Those Who Did Not Travel and Sleep Outside the City.

The cumulative hazard of having a malaria attack within one year for those participants who travelled and slept in rural areas (outside the city) versus those who did not was calculated and is presented as a life table to display the number of subjects at risk, the number with first clinical episode and the number censored at each time point. Participants are right-censored at the time of first malaria episode. Participants who did not develop malaria during follow-up or were lost to follow-up were censored at the time of their last visit. (NCT00379821)
Timeframe: Days 0 - 420

,
Interventionparticipants (Number)
Days 0-27 - Number At RiskDays 0-27 - Number with MalariaDays 0-27 - Number CensoredDays 28-55 - Number At RiskDays 28-55 - Number with MalariaDays 28-55 - Number CensoredDays 56-83 - Number At RiskDays 56-83 - Number with MalariaDays 56-83 - Number CensoredDays 84-111 - Number At RiskDays 84-111 - Number with MalariaDays 84-111 - Number CensoredDays 112-139 - Number At RiskDays 112-139 - Number with MalariaDays 112-139 - Number CensoredDays 140-167 - Number At RiskDays 140-167 - Number with MalariaDays 140-167 - Number CensoredDays 168-195 - Number At RiskDays 168-195 - Number with MalariaDays 168-195 - Number CensoredDays 196-223 - Number At RiskDays 196-223 - Number with MalariaDays 196-223 - Number CensoredDays 224-251 - Number At RiskDays 224-251 - Number with MalariaDays 224-251 - Number CensoredDays 252-279 - Number At RiskDays 252-279 - Number with MalariaDays 252-279 - Number CensoredDays 280-307 - Number At RiskDays 280-307 - Number with MalariaDays 280-307 - Number CensoredDays 308-335 - Number At RiskDays 308-335 - Number with MalariaDays 308-335 - Number CensoredDays 336-363 - Number At RiskDays 336-363 - Number with MalariaDays 336-363 - Number CensoredDays 364-391 - Number At RiskDays 364-391 - Number with MalariaDays 364-391 - Number CensoredDays 392 - 420 - Number At RiskDays 392 - 420 - Number with MalariaDays 392 - 420 - Number Censored
Participants Who Did Not Travel and Sleep Outside the City20102817341015991613412101124510327941390497716701564435752503740038202
Participants Who Traveled and Slept Outside the City43206336913263301121298121627013172403222153161964161761241601281407412988113821032100101

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 0 of initial malaria episode (Episode 0)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate27.2
Chloroquine Plus Atovaquone-Proguanil32.1
CQ Plus Azithromycin27.5
CQ Monotherapy26.2

[back to top]

"Number of Participants in Each Treatment Arm Who Change From Normal to Abnormal on Any Questions of the Neurological Examination"

"A basic age-appropriate neurological examination was conducted on Day 28 of each malaria illness episode and also at Days 112 and 224, and at 1 year. Subjects were were counted as a change from 'normal' to 'abnormal' if they had the 'normal' (or not-applicable) response for the initial day 28 exam and an 'abnormal' response at their last exam. If a subject did not have an exam at 1 year then the last available exam that was not associated with an illness episode (either Day 112 or 224) was used." (NCT00379821)
Timeframe: 1 Year

InterventionParticipants (Number)
Chloroquine Plus Artesunate6
Chloroquine Plus Atovaquone-Proguanil4
CQ Plus Azithromycin3
CQ Monotherapy12

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 0 of first subsequent malaria episode (Episode 1)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Artesunate24.2
Chloroquine Plus Atovaquone-Proguanil21.7
CQ Plus Azithromycin22.4
CQ Monotherapy25.3

[back to top]

Mean Alanine Transaminase (ALT) in Each Treatment Arm (Hepatic Function)

ALT values were assessed from blood draws at Day 0 and Day 14 of each malaria episode. (NCT00379821)
Timeframe: Day 0 of fourth subsequent malaria episode (Episode 4)

InterventionInternational Units/Liter (Mean)
Chloroquine Plus Atovaquone-Proguanil27.3
CQ Plus Azithromycin24.9

[back to top]

Pharmacokinetics of Chloroquine Represented by Time of Maximal Concentration (Tmax) and Chloroquine Half-life

1727 non-zero concentration measurements from 479 participants were pooled and used for population pharmacokinetic modeling in Monolix413s. Compartmental population pharmacokinetic modeling was used due to highly sparse data. The model was parameterized in terms of absorption rate constant for chloroquine (Ka), apparent clearance for chloroquine (CL/F, with F as the unknown oral bioavailability), apparent volume of distribution of the central and peripheral compartments for chloroquine (Vd/F), and the inter-compartmental clearance for chloroquine (Q/F). Only these primary population pharmacokinetic parameters could be estimated using the type of data collected. The best-fit population PK model was then used to estimate individual parameter estimates to derive Tmax and half-life. (NCT00379821)
Timeframe: Day 0 - Day 28

,,,
InterventionHours (Median)
Time of maximal concentration (Tmax)Chloroquine half-life
Chloroquine Plus Artesunate5.641.6
Chloroquine Plus Atovaquone-Proguanil5.646.2
CQ Monotherapy5.644.5
CQ Plus Azithromycin5.541.3

[back to top]

Relationship Between Changes in Auditory Function and Treatment Groups

ABR Wave III latency (ms) changes from baseline to Day 7 in the three drug exposure groups. (NCT00444106)
Timeframe: From Baseline to Day 7

,,
Interventionms (Mean)
Baseline Right EarChange from baseline to Day 7 Right EarBaseline Left EarChange from baseline to Day 7 Left Ear
Artemether-lumefantrine (Coartem)3.860.013.850.01
Artesunate-mefloquine3.86-0.043.82-0.03
Atovaquone-proguanil (Malarone)3.89-0.013.88-0.01

[back to top]

Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test)

"To demonstrate the safety of artemether-lumefantrine after 3 days of treatment in patients with acute, uncomplicated falciparum malaria by testing the null hypothesis that the rate of auditory abnormalities is ≥ 15% in the population treated with artemether-lumefantrine as assessed by ABR at Day 7 following initiation of treatment compared with their baseline values. An auditory nerve abnormality is here defined as a greater than 0.30 ms change in Wave III latency from baseline to Day 7. Exact Pearson-Clopper two-sided 95% confidence limits were constructed for all three treatment groups." (NCT00444106)
Timeframe: 7 days

InterventionPercentage of Participants (Number)
Artemether-lumefantrine (Coartem)2.6

[back to top]

Auditory Changes Following 3 Days of Treatment at Days 3, 7, 28, and 42 Days as Assessed by Pure Tone Thresholds Assessments (a Type of Hearing Test)

Audiometric measurements such as pure-tone threshold (air conduction tested at 250 to 8000 HZ) day 3, 7, 28 and 42 following initiation of treatment, including changes from baseline. Pure-tone average (PTA) calculated for each ear by averaging the pure-tone threshold values at 500, 1000, 2000 and 3000 HZ. (NCT00444106)
Timeframe: Baseline (Day 1), 3, 7, 28 and Day 42

,,
InterventiondB (Mean)
Baseline Right EarChange from baseline to Day 3 Right EarChange from baseline to Day 7 Right EarChange from baseline to Day 28 Right EarChange from baseline to Day 42 Right EarBaseline Left EarChange from baseline to Day 3 Left EarChange from baseline to Day 7 Left EarChange from baseline to Day 28 Left EarChange from baseline to Day 42 Left Ear
Artemether-lumefantrine12.2-2.5-2.2-2.7-3.011.4-1.2-1.7-2.0-1.5
Artesunate-mefloquine12.7-1.9-2.6-3.6-3.112.5-1.2-1.4-2.5-3.0
Atovaquone-proguanil (Malarone)12.0-2.4-2.6-2.6-3.311.3-1.5-1.3-1.8-2.1

[back to top]

Efficacy of Polymerase Chain Reaction (PCR) Adjusted Malaria Cure Rates of the Three Treatment Regimens at Days 14, 28 and 42

Percentage of patients with clearance of asexual parasitemia (observed by optical microscopy) within 7 days of initiation of trial treatment without recrudescence within 14, 28 and 42 days respectively after initiation of treatment. Patients with recurrent parasitemia and paired PCR results were classified as either a new infection (different paired genotypes) or a recrudescence (matching paired genotypes). Patients without paired PCR results or ambiguous results were classified as treatment failures. (NCT00444106)
Timeframe: Days 14, 28 and 42

,,
InterventionPercentage of Participants (Number)
Day 14Day 28Day 42
Artemether-lumefantrine (Coartem)99.498.797.5
Artesunate-mefloquine98.198.198.1
Atovaquone-proguanil (Malarone)100.098.198.1

[back to top]

Measured Concentrations of Plasma Atovaquone With Determinations of T1/2.

Plasma concentrations (ng/ml) were used to determine the elimination half life (t1/2) of atovaquone (days). (NCT00984256)
Timeframe: 7, 6, 5, and 1 day prior to challenge; on the day of the challenge; 1, 4, 5, 6, 7, 8, 10and 14 days after the challenge; and on the day parasitemia develops.,

InterventionDays (Mean)
Prophylaxis Group 13.3
Prophylaxis Group 23.3
Prophylaxis Group 33.3
Prophylaxis Group 45.6
Prophylaxis Group 53.7

[back to top]

Measured Concentrations of Plasma Atovaquone With Determinations of Area Under the Curve

Plasma concentrations were used to determine the pharmacokinetic curves with determinations of area under the curve (AUC).The smallest AUC Day 0-6.5 associated with protection from detectable parasitemia, and the highest AUC Day 0-6.5 observed in any cases of malaria (prophylactic failures) were to be reported. (NCT00984256)
Timeframe: 7, 6, 5, and 1 day prior to challenge; on the day of the challenge; 1, 4, 5, 6, 7, 8, 10and 14 days after the challenge; and on the day parasitemia develops.,

Interventionng*day/ml (Mean)
Treatment Group 13595
Treatment Group 2616
Treatment Group 3510
Treatment Group 41434
Treatment Group 52233

[back to top]

Prophylactic Efficacy of 3 Different Doses of Atovaquone/Proguanil (Malarone@) Given 1 Week Before Infectious Sporozoite Challenge Using the P. Falciparum Human Challenge Model.

Number of participants with prophylactic efficacy was determined by the absence of cases of malaria parasitemia, defined as microscopically detectable parasitemia by Giemsa-stained thick smears, in those receiving any dose of Malarone as compared to the control (no treatment) group (NCT00984256)
Timeframe: Days 6-20

Interventionparticipants with negative parasitemia (Number)
Treatment Group 16
Treatment Group 24
Treatment Group 33
Treatment Group 46
Treatment Group 55
Control0

[back to top]

Number of Participants With Adverse Events as a Measure of Safety & Tolerability of DSM265

Safety & tolerability of DSM265 for causal and suppressive chemoprophylaxis in non-immune healthy volunteers in a non-immune healthy volunteers in CHMI with PfSPZ challenge. (NCT02450578)
Timeframe: From first dose (Day -1 in Cohort 1A and Day -7 in Cohort 2) to Day 60 post-inoculum

InterventionParticipants (Count of Participants)
Cohort 1a: DSM265/Placebo, Sporozoite Inoculum5
Cohort 2: DSM265/Placebo, Sporozoite Inoculum6

[back to top]

Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Plasmodium Falciparum Sporozoite Challenge Inoculum

Safety & tolerability of Plasmodium falciparum sporozoite challenge inoculum during DSM265 administration, and Malarone administration. Measured by adverse events, laboratory data (NCT02450578)
Timeframe: Day 0 to Day 60 post-inoculum

InterventionParticipants (Count of Participants)
Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)3
Cohort 1B: Malarone, Sporozoite Challenge5
Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)5
Placebo Cohorts 1A and 24

[back to top]

Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety & Tolerability of Malarone

"Safety & tolerability of Malarone for causal and suppressive chemoprophylaxis in non-immune healthy volunteers in a Plasmodium falciparum sporozoite challenge. Measured by adverse events, laboratory data.~Malarone® was administered as a single daily dose over a period of 9 days from Day -1 to Day 7." (NCT02450578)
Timeframe: From first dose (Day -1, Cohort 1b) to Day 60 post-inoculum

InterventionParticipants (Count of Participants)
Cohort 1B: Malarone, Sporozoite Challenge5

[back to top]

Pre-patent Period

"The pre-patent period is defined as the time (days) from inoculation with PfSPZ to first occurrence of a positive TBS. If no positive TBS is seen by Day 28, this variable is set to 28 days.~Complete protection = Subjects showing with pre-patent period equal to 28 days." (NCT02450578)
Timeframe: Day 0 to Day 28 post-inoculum (daily)

InterventionDays (Geometric Mean)
Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)28.0
Cohort 1B: Malarone, Sporozoite Challenge28.0
Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)20.6
Placebo Cohorts 1A and 211.7

[back to top]

DSM265 Pharmacokinetics Profile - AUC 0-∞, AUC 0-168h, and AUC 0-480h

Pre-dose and post-dose during the period including Day 28 for AUC 0-∞, AUC 0-168h, and AUC 0-480h (NCT02450578)
Timeframe: From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum

,
Interventionng*h/mL (Geometric Mean)
AUC 0-∞ DBSAUC 0-∞ PlasmaAUC 0-168h DBSAUC 0-168h PlasmaAUC 0-480h DBSAUC 0-480h Plasma
Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)979000187000058200011000008630001680000
Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)90600015400005680009490008470001430000

[back to top]

DSM265 Pharmacokinetics Profile - C Max

Pre-dose and post-dose during the period including Day 28 (NCT02450578)
Timeframe: From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum

,
Interventionng/mL (Geometric Mean)
C max DBSC max Plasma
Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)686013300
Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)699011200

[back to top]

DSM265 Pharmacokinetics Profile - CL/F

Pre-dose and post-dose during the period including Day 28 (NCT02450578)
Timeframe: From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum

,
InterventionmL/h (Geometric Mean)
CL/F DBSCL/F Plasma
Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)409214
Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)441260

[back to top]

DSM265 Pharmacokinetics Profile - T 1/2

Pre-dose and post-dose during the period including Day 28 (NCT02450578)
Timeframe: From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum

,
Interventionhours (Geometric Mean)
t 1/2 DBSt 1/2 Plasma
Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)132134
Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)113116

[back to top]

DSM265 Pharmacokinetics Profile - T Max

Pre-dose and post-dose during the period including Day 28 (NCT02450578)
Timeframe: From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum

,
Interventionhours (Median)
T max DBST max Plasma
Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)2.022.00
Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)8.488.48

[back to top]

DSM265 Pharmacokinetics Profile - Vz/F

Pre-dose and post-dose during the period including Day 28 (NCT02450578)
Timeframe: From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum

,
InterventionmL (Geometric Mean)
Vz/F DBSVz/F Plasma
Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)7790041400
Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)7170043600

[back to top]

DSM450 Pharmacokinetics Profile - AUC 0-t, AUC 0-168h, and AUC 0-480h

Pre-dose and post-dose during the period including Day 28 for AUC 0-t, AUC 0-168h, and AUC 0-480h (NCT02450578)
Timeframe: From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum

,
Interventionng*h/mL (Geometric Mean)
AUC 0-∞ DBSAUC 0-∞ PlasmaAUC 0-168h DBSAUC 0-168h PlasmaAUC 0-480h DBSAUC 0-480h Plasma
Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)18500032600063800115000185000326000
Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)22500036700085300142000234000375000

[back to top]

DSM450 Pharmacokinetics Profile - T Max

Pre-dose and post-dose during the period including Day 28 (NCT02450578)
Timeframe: From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum

,
Interventionhours (Median)
t max DBSt max Plasma
Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)169169
Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)216169

[back to top]

DSM450 Pharmacokinetics Profile - Cmax

Pre-dose and post-dose during the period including Day 28 (NCT02450578)
Timeframe: From pre-dose of DSM265 (Day -1 in Cohort 1a and Day -7 in Cohort 2) to Day 28 post-inoculum

,
Interventionng/mL (Geometric Mean)
Cmax DBSCmax Plasma
Cohort 1A: 400 mg DSM265 (Day-1), Sporozoite Challenge (Day0)545999
Cohort 2: 400 mg DSM265 (Day-7), Sporozoite Challenge (Day0)7141170

[back to top]

GMT Over Protective Titer Prior to Third Dose of PCECV

Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3, 7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of >0.5 IU/ml against rabies virus as protective. (NCT02564471)
Timeframe: 21 days for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and 7 days for Rabies Arm

InterventionIU/ml (Geometric Mean)
Chloroquine0.14
Atovaquone and Proguanil (Malarone)0.11
Doxycycline0.16
Rabies0.17

[back to top]

Geometric Mean Titer (GMT) 14 Days Post Fourth Dose Post Exposure Prophylaxis (PEP) With Purified Chick Embryo Cell Vaccine (PCECV) in Each Malaria Prophylaxis Group Compared to Control to Determine if a Fifth Dose of PEP Would Add Value

Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21, and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3,7 and 14 (dose 4). Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of >0.5 IU/ml against rabies virus as protective. Descriptive analyses were based on samples taken 14 days after dose 4, (e.g., at 6 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Arms and at 4 weeks for Rabies Arm). (NCT02564471)
Timeframe: 6 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and at 4 weeks for Rabies Group

InterventionIU/ml (Geometric Mean)
Chloroquine3.45
Atovaquone and Proguanil (Malarone)7.95
Doxycycline8.51
Rabies10.26

[back to top]

GMT Over Protective Titer 28 Days Post Fourth Dose of PCECV

Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3,7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of >0.5 IU/ml against rabies virus as protective. (NCT02564471)
Timeframe: Up to 8 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and up to 6 weeks for Rabies Arm

InterventionIU/ml (Geometric Mean)
Chloroquine2.3
Atovaquone and Proguanil (Malarone)4.96
Doxycycline5.18
Rabies6.87

[back to top]

GMT Over Protective Titer Prior Fourth Dose of PCECV

Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3, 7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of >0.5 IU/ml against rabies virus as protective. (NCT02564471)
Timeframe: 28 days for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and 14 days for Rabies Arm

InterventionIU/ml (Geometric Mean)
Chloroquine4.15
Atovaquone and Proguanil (Malarone)6.45
Doxycycline7.04
Rabies6.98

[back to top]

AUC Gametocytes

The area under the curve of gametocyte density versus time. The median AUC was calculated for both cohorts. Since onset of gametocytaemia differs depending on method of infection a window of 15 days was used to calculate AUC, from the time-point where a minimum of 50% of participants within a cohort had detectable gametocytemia. (NCT03454048)
Timeframe: up to day 51 after challenge infection

Intervention(gametocytes*days)/mL (Median)
Cohort A99
Cohort B11043

[back to top]

Frequency of Adverse Events in the CHMI-trans Model

Frequency of adverse events in the CHMI-trans model. (NCT03454048)
Timeframe: up to day 51 after challenge infection

InterventionAdverse events (Number)
Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP95
Group 2 (Cohort A) LD-PIP/LD-PIP2/SP95
Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP107
Group 4 (Cohort B) LD-PIP/LD-PIP2/SP52

[back to top]

Gametocyte Commitment

The gametocyte commitment rate is estimated by dividing the peak gametocyte by the peak of asexual parasites. (NCT03454048)
Timeframe: up to day 51 after challenge infection

Interventiongametocytes/asexual parasite (Median)
Cohort A0.0011
Cohort B0.0323

[back to top]

Gametocyte Prevalence

Number of individuals in each study arm that show prevalence of gametocytes as defined by quantitative reverse-transcriptase PCR (qRT-PCR) for CCp4 (female) and PfMGET (male) mRNA with a threshold of 5 gametocytes/mL for positivity. (NCT03454048)
Timeframe: up to day 51 after challenge infection

InterventionParticipants (Count of Participants)
Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP5
Group 2 (Cohort A) LD-PIP/LD-PIP2/SP6
Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP6
Group 4 (Cohort B) LD-PIP/LD-PIP2/SP6

[back to top]

Gametocyte Sex-ratio

Proportion of male gametocytes (NCT03454048)
Timeframe: up to day 51 after challenge infection

InterventionProportion of male gametocytes (Median)
Cohort A0.20
Cohort B0.31

[back to top]

Number of Participants Infectious for Mosquitoes Through DFA

Prevalence of gametocyte infectiousness for Anopheles mosquitoes through Direct Feeding Assays (Direct Skin Feeding Assay, DFA). (NCT03454048)
Timeframe: up to day 51 after challenge infection

InterventionParticipants (Count of Participants)
Cohort A0
Cohort B9

[back to top]

Peak Density Gametocytes

Peak density of gametocytes by qRT-PCR. (NCT03454048)
Timeframe: up to day 51 after challenge infection

InterventionGametocytes/mL (Median)
Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP13.9
Group 2 (Cohort A) LD-PIP/LD-PIP2/SP21.4
Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP1442.2
Group 4 (Cohort B) LD-PIP/LD-PIP2/SP813.2

[back to top]

Magnitude of Adverse Events in the CHMI-trans Model

"symptoms will be ranked as (1) mild, (2) moderate, or (3) severe, depending on their intensity according to the following scale:~Mild (grade 1): awareness of symptoms that are easily tolerated and do not interfere with usual daily activity~Moderate (grade 2): discomfort that interferes with or limits usual daily activity~Severe (grade 3): disabling, with subsequent inability to perform usual daily activity, resulting in absence or required bed rest" (NCT03454048)
Timeframe: up to day 51 after challenge infection

,,,
InterventionAdverse events (Number)
Mild (grade I)Moderate (grade II)Severe (grade III)
Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP64229
Group 2 (Cohort A) LD-PIP/LD-PIP2/SP562217
Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP86174
Group 4 (Cohort B) LD-PIP/LD-PIP2/SP4183

[back to top]

Frequency of Adverse Events After NF135.C10 CPS Immunization

The number of adverse events will be recorded by the trial clinicians for all participants. (NCT03813108)
Timeframe: Cohort A: Inclusion until 35 days after challenge infection (35 weeks) Cohort B: Inclusion - premature end of study (22 weeks)

InterventionAdverse events (Number)
1: NF135 CPS-immunization Challenged by NF135139
2: Low Dose NF135 CPS-immunization Challenged by NF135173
3: NF135 CPS-immunization (A/L) Cohort B172

[back to top]

Magnitude of Adverse Events After NF135.C10 CPS Immunization

The severity of adverse events will be recorded (mild/moderate/severe) for each adverse event (NCT03813108)
Timeframe: Cohort A: Inclusion until 35 days after challenge infection (35 weeks) Cohort B: Inclusion - premature end of study (22 weeks)

,,
InterventionAdverse events (Number)
Mild adverse events (grade 1)Moderate adverse events (grade 2)Severe adverse events (grade 3)Serious adverse events (grade 4)
1: NF135 CPS-immunization Challenged by NF13510820110
2: Low Dose NF135 CPS-immunization Challenged by NF13512835100
3: NF135 CPS-immunization (A/L) Cohort B12131191

[back to top]

Break Through Infections

Number of subjects that required rescue treatment with atovaquone/proguanil due to a positive thick smear in combination with symptoms following NF135.C10 immunizations despite mefloquine prophylaxis (Cohort A) or presumptive artemether/lumefantrine treatment (Cohort B). (NCT03813108)
Timeframe: From day 0 until 28 days after each immunization (28 days)

,
Interventionparticipants (Number)
Break through following immunization 1Break through following immunization 2Break through following immunization 3
1: NF135 CPS-immunization Challenged by NF1351034
2: Low Dose NF135 CPS-immunization Challenged by NF1351035

[back to top]

Break Through Infections

Number of subjects that required rescue treatment with atovaquone/proguanil due to a positive thick smear in combination with symptoms following NF135.C10 immunizations despite mefloquine prophylaxis (Cohort A) or presumptive artemether/lumefantrine treatment (Cohort B). (NCT03813108)
Timeframe: From day 0 until 28 days after each immunization (28 days)

Interventionparticipants (Number)
Break through following immunization 1
3: NF135 CPS-immunization (A/L) Cohort B2

[back to top]

Time to Parasitemia

The effectiveness of CPS-immunization with NF135 sporozoites to protect against malaria challenge infection with homologous N135.C10 or heterologous NF54 sporozoites will be determined by the time to parasitemia in immunized versus non-immunized volunteers after the challenge infection. (NCT03813108)
Timeframe: Day 1 - 28 after malaria challenge infection (28 days)

Interventiondays to parasitaemia (Median)
1: NF135 CPS-immunization Challenged by NF1359
2: Low Dose NF135 CPS-immunization Challenged by NF1357
5: Control Group Challenged by NF135.C10 Cohort A7

[back to top]

Secondary Between Group Differences in Viral Load

Change in viral load at Day 3, 5, and 7 days. This shows the group differences between intervention and placebo and log 10 viral load at specific days 3, 5, and 7 for atovaquone arm and placebo arm. (NCT04456153)
Timeframe: baseline to day7

,,
Interventionlog 10 (copies/mL) (Mean)
day 1 to 3day 1 to 5day 1 to 7
Atovaquone Plus Standard of Care5.3424.3293.804
Difference Between Atovaquone and Placebo0.1290.107-0.766
Placebo Plus Standard of Care4.4063.7604.108

[back to top]

Stratifed by Remdesivir

change in log RNA 10 day 1 to 10 stratified by remdesivir by GLMM (NCT04456153)
Timeframe: day 10

Interventionlog 10 RNA copies/mL (Mean)
Stratified With Remdesivir-0.754
Stratified Without Remdesivir-2.010

[back to top]

Primary Analysis

Between group differences in viral load (Log copy number/ml) using generalized linear mixed-effect models of repeated measures (GLMM), using data from all available samples (NCT04456153)
Timeframe: Day 1 to Day 10

Interventionlog 10 (copies/mL) (Mean)
Overall Group-1.906
Atovaquone Group With Standard of Care Treatment2.629
Placebo Plus Standard of Care4.073

[back to top]

Percentage With 2 Log Viral Load Drop at Day 3

Between group comparison of time to drop in viral load (Log copy number/ml) of 2 log units using Kaplan-Meier estimation. Examined the percentage of participants who achieved this viral load drop in 3 days. (NCT04456153)
Timeframe: baseline to day 3

Interventionpercentage of participants (Number)
Atovaquone15
Placebo20

[back to top]

Change in Viral Load at Day 10 Stratified by Sex

Between group differences in viral load (Log copy number/ml) using GLMM stratified by (NCT04456153)
Timeframe: baseline to day 10

Interventionlog 10 viral load (copies/mL) (Mean)
Stratified by Sex: Men-1.8732
Stratified by Sex: Women0.555

[back to top]

Area Under the Curve Copies/ml*Day at Day 7

"This is a alternative method of measurement of area which examines the viral load ( copies/ml )(y-axis) by day (x-axis) using the trapezoidal method. The area under the curve was calculated via the trapezoidal rule. As such, this is a numeric value that is different than the traditional use of the term mean or median. However, in order to calculate a measure of error associated with this quantity, bootstrapping with 500 replications would need to be performed to assess statistical significance or lack thereof. The mean of the bootstrap samples could be reported as the mean area under the curve." (NCT04456153)
Timeframe: day 7

Interventioncopies/mL*day (Number)
Atovaquone38.39
Placebo36.09

[back to top]

Number of Participants With Change in Ordinal Scale ≥2 Points by Day 15.

Ordinal scale 1 indicated death, and higher scores were various degrees of hospitalizations and incapacity to being out of hospital. Ordinal Scale 1-7 with higher score indicating improvement in clinical status. Change of ≥2 points on the ordinal scale by Day 15 using chi-square analysis (NCT04456153)
Timeframe: Day 15

InterventionParticipants (Count of Participants)
Atovaquone25
Placebo9

[back to top]